Découvrez nos professeurs et professeures!

Pierre Marquet

Médecin clinicien enseignant titulaire

Pierre Marquet
Centre d'optique, photonique et laser
Centre thématique de recherche en neurosciences
Centre de recherche CERVO
Partager la fiche :

Contribution à la recherche

Axe de recherche de l'Université Laval :

Santé et bien-être durables

Thématiques de recherche de la Faculté de médecine :

Neurosciences et santé mentale

Domaines et intérêts de recherche du (de la) professeur(e) :

Neurosciences, santé mentale et toxicomanies
  • Schizophrénie
  • Troubles affectifs (de l'humeur)
  • Dépression
  • Autisme
  • Modélisation neuronale
  • Activité nerveuse et synaptique
  • Communication neuronale et neurotransmission
  • Développement du système nerveux
  • Greffes neuronales et cellules souches
  • Métabolisme cérébral
  • Plasticité/régénération neuronale
  • Récepteurs et transporteurs
  • Signalisation cellulaire
Individu
Famille
Cellulaire
  • Cellule
Subcellulaire
Organismes vivants (êtres humains - Psychologie/aspects biologiques)
Outils de caractérisation
  • Propriétés thermodynamiques
Intelligence artificielle
  • Systèmes neuronaux

Projets de recherche

  • Centre d'optique, photonique et lasers - École polytechnique de Montréal, Université du Québec à Trois-Rivières, École de technologie supérieure, Université de Sherbrooke, Université Concordia, Université Laval - Fonds internes, Institut national de recherche scientifique (INRS), Fonds de recherche du Québec - Nature et technologies, Université McGill - Regroupements stratégiques NT, co-chercheur - 2024-04-01 au 2030-03-31
  • Unité mixte internationale (UMI) en neuro-développement et psychiatrie de l’enfant - Université Laval - Fonds internes - BDR - Contributions, chercheur principal - 2023-05-17 au 2030-03-31
  • Development of a methodology based on digital holographic microscopy to study cell homeostasis by measuring cell volume dynamics and water fluxes - Conseil de recherches en sciences naturelles et génie Canada - Subventions à la découverte SD (individuelles et d'équipe), chercheur principal - 2024-04-01 au 2029-03-31
  • Repousser les frontières de l'étude de la biologie à l'échelle nanométrique en conditions naturelles - Fondation Canadienne pour l'innovation (La), CIUSSS - CN - CERVO, Ministère de la Santé et des Services sociaux - Fonds d'innovation (FI), co-chercheur - 2023-07-01 au 2025-03-31
  • Développement d'un imageur pour diagnostiquer les troubles de l'humeur aux points de services - Secrétariat des programmes interorganismes à l’intention des établissements - Sentinelle Nord - Fonds de maturation, chercheur principal - 2023-01-01 au 2024-12-31
  • Smart, adaptative, and autonomous sensing - Université Laval - Fonds internes, Sentinelle Nord (usage exclusif VRRCI), Conseil de recherches en sciences naturelles et génie Canada, Secrétariat Inter-Conseils (Canada) (CRSH, CRSNG, IRSC) - Programme de formation orientée vers la nouveauté, la collaboration et l'expérience en recherche (FONCER), co-chercheur - 2017-04-01 au 2024-03-31
  • Centre d'optique photonique et laser (COPL) - Université de Sherbrooke, École polytechnique de Montréal, Université McGill, Université Concordia, Fonds de recherche du Québec - Nature et technologies, École de technologie supérieure, Université Laval - Fonds internes - Regroupements stratégiques NT, co-chercheur - 2017-04-01 au 2024-03-31
  • Unveiling comprehensive cellular biophysical properties using quantitative phase digital holographic microscopy - Secrétariat Inter-Conseils (Canada) (CRSH, CRSNG, IRSC), Conseil de recherches en sciences naturelles et génie Canada - Subventions à la découverte SD (individuelles et d'équipe), chercheur principal - 2018-04-01 au 2023-03-31
  • Support de Sentinelle Nord à l'Unité mixte internationale en psychiatrie et neurodéveloppement - Secrétariat des programmes interorganismes à l’intention des établissements - Fonds d'excellence en recherche Apogée Canada, chercheur principal - 2015-09-01 au 2023-03-31
  • Repetitive transcranial magnetic stimulation to prevent mental health disorders - Secrétariat des programmes interorganismes à l’intention des établissements - Nouvelles frontières en recherche, co-chercheur - 2022-03-01 au 2023-02-28
  • Chaire d'excellence en recherche du Canada en neurophotonique - Instituts de recherche en santé du Canada, Université Laval - Fonds internes - Programme de chaires d'excellence en recherche du Canada, chercheur principal - 2015-01-01 au 2021-12-31
  • Télé-NEUROS (Nouvel Environnement Universitaire de Recherche Orchestrée en Santé mentale et cognitive: une télé initiative) - CIUSSS - CN - CIRRIS, Université Laval - Fonds internes, CIUSSS - CN - CERVO, co-chercheur - 2020-10-20 au 2021-03-31

Publications

  • Buprenorphine and norbuprenorphine determination in urine and serum by liquid chromatography mass spectrometry with electrospray-type ionization., Lachatre, G, Dreyfuss, MF, Dupuy, JL, Lotfi, H, Verneuil, B, Marquet, P, Hoja, H, Analusis, 1996
  • Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients, Marquet, Pierre, Samuel, Didier, Sautereau, Denis, Loustaud-Ratti, Veronique, Sebagh, Mylene, Picard, Nicolas, Woillard, Jean-Baptiste, Debette-Gratien, Marilyne, Transplantation, 2016, 10.1097/TP.0000000000001394
  • Bayesian Estimation of Mycophenolate Mofetil in Lung Transplantation, Using a Population Pharmacokinetic Model Developed in Kidney and Lung Transplant Recipients, Rousseau, Annick, Marquet, Pierre, Estenne, Marc, Knoop, Christiane, Guillemain, Romain, Stern, Marc, Dromer, Claire, Reynaud-Gaubert, Martine, Kessler, Romain, Pison, Christophe, Premaud, Aurelie, Monchaud, Caroline, de Winter, Brenda C. M., Clinical Pharmacokinetics, 2012
  • FP7 BIOMARGIN: SMALL SETS OF URINARY CELL mRNAs LEADING TO A PARTITION TREE ON KIDNEY ALLOGRAFT LESIONS, Anglicheau, D., Marquet, P., Essig, M., Gwinner, W., Naesens, M., Gazut, S., Morin, L., Benon, A., Tinel, C., Transplant International, 2018
  • POPULATION PHARMACOKINETICS OF AMIKACIN IN INTENSIVE-CARE UNIT PATIENTS STUDIED BY NPEM ALGORITHM, LACHSATRE, G, MERLE, L, LOTFI, H, MARQUET, P, VOULTOURY, JC, PESSIS, C, DEBORD, J, Fundamental & Clinical Pharmacology, 1995
  • PHARMACOEPIDEMIOLOGICAL STUDY IN RENAL TRANSPLANTATION: COMPARISON OF DIFFERENT TOOLS FOR THE COLLECTION OF DATA ON TREATMENTS, SIDE EFFECTS AND COMPLIANCE., Essig, M., Rostaing, L., Laroche, M., Montastruc, J., Moore, N., Kamar, N., Merville, P., Marquet, P., Clinical Pharmacology & Therapeutics, 2010
  • STEROID-FREE REGIMEN AND OPTIMIZATION OF MYCOPHENOLIC ACID (MPA) EXPOSURE IN LIVER TRANSPLANT RECIPIENTS: FINAL RESULTS OF CELLESTE, Rostaing, Lionel, Taguieva, Naila, Dur, Carole, Marquet, Pierre, Vanlemmens, Claire, Hardwigsen, Jean, Dharancy, Sebastien, Pageaux, Georges-Philippe, Duvoux, Christophe, Altieri, Mario, Calmus, Yvon, Neau-Cransac, Martine, Leroy, Vincent, Radenne, Sylvie, Gugenheim, Jean, Durand, Francois, Saliba, Faouzi, Transplant International, 2012
  • Population Pharmacokinetic Modeling Approach to compare different amikacin dose rates in children with cystic fibrosis: are we efficient enough?, Woillard, J. B., Marquet, P., Saint-Marcoux, F., Bui, S., Woloch, C., Bouchet, S., Lakdhari, A., Fundamental & Clinical Pharmacology, 2016
  • Uterine allotransplantation in ewes using an aortocava patch, Aubard, Y., Essig, M., Cornuejols, M. J., Couquet, C., Plainard, X., Pommepuy, I., Marquet, P., Piver, P., Saint Marcoux, F., Maubon, A., Fourcade, L., Bertin, F., Gauthier, T., Human Reproduction, 2011, 10.1093/humrep/der288
  • A multivariate genetic analysis of glucuronidation and biliary excretion gene polymorphisms associated with mycophenolate acid related diarrhea in renal transplant patients, Marquet, P., Le Meur, Y., Drouet, M., Rerolle, J. P., Rousseau, A., Picard, N., Woillard, J. B., Fundamental & Clinical Pharmacology, 2009
  • Population pharmacokinetic/pharmacogenetic modeling and design of a bayesian estimator for the therapeutic drug monitoring of tacrolimus in lung transplantation, Rousseau, A., Marquet, P., Guillemain, R., Kessler, R., Stern, M., Pison, C., Reynaud-Gaubert, M., Estenne, M., De Winter, B., Monchaud, C., Fundamental & Clinical Pharmacology, 2011
  • Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on acyl-MPAG production in vitro and in adult renal transplant patients, Marquet, Pierre, Le Meur, Yann, Rerolle, Jean-Philippe, Picard, Nicolas, Djebli, Nassim, Pharmacogenetics and Genomics, 2007
  • Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs, Haufroid, Vincent, Hesselink, Dennis A., Wallemacq, Pierre, van Gelder, Teun, Marquet, Pierre, Bergan, Stein, Picard, Nicolas, Therapeutic Drug Monitoring, 2016
  • Metabolic interactions of benzodiazepines with oxycodone ex vivo and toxicity depending on usage patterns in an animal model., El Balkhi S, Saint-Marcoux F, Marquet P, Picard N, Trouillas P, Otyepka M, Bazgier V, Javellaud J, Zarrouk E, Čechová P, Lawson R, British journal of pharmacology, 2022, 10.1111/bph.15765
  • APOMYGRE: a multicenter trial which validates mycophenolate mofetil therapeutic drug monitoring in de novo kidney transplant recipients, Le Meur, Y., Jacqz-Aigrain, E., Saivin, S., Debruyne, D., Turcant, A., Loichot, C., Hary, L., Compagnon, P., Hoizey, G., Debord, J., Rousseau, A., Marquet, P., Fundamental & Clinical Pharmacology, 2007
  • How has the future investment program stimulated research and innovation in health?, Zins M, Mahfoudi A, Lyonnet S, Garbil B, Froguel P, Duluc G, Debette S, Boitard C, Beretz A, Benhabiles N, Le Jeunne C, Vacaresse E, Dantonel JC, Bordet R, Therapie, 2022, 10.1016/j.therap.2022.01.009
  • Dexamethasone in resting and exercising men. I. Effects on bioenergetics, minerals, and related hormones, Galen, FX, Habrioux, G, Chassain, AP, Lac, G, Marquet, P, Journal of Applied Physiology, 1999
  • A Prognostic Tool for Individualized Prediction of Graft Failure Risk within Ten Years after Kidney Transplantation, , Journal of Transplantation, 2019, 10.1155/2019/7245142
  • Development of a population model and a bayesian estimator for Envarsus (R) in liver transplantation, Marquet, P., Saint-Marcoux, F., Monchaud, C., Debord, J., Woillard, J. B., Fundamental & Clinical Pharmacology, 2017
  • THE ACTIVITY OF ANTIBODY-MEDIATED REJECTION IN KIDNEY TRANSPLANTATION IS REFLECTED BY ACTIVATED NATURAL KILLER CELL TRANSCRIPTS: THE BIOMARGIN STUDY, Naesens, M., Marquet, P., Essig, M., Gwinner, W., Anglicheau, D., Yazdani, S., Gazut, S., Transplant International, 2017
  • Monitoring of adherence to calcineurin inhibitors using their longitudinal exposures in kidney transplant patients, Premaud, A., Rousseau, A., Marquet, P., Essig, M., Monchaud, C., Villeneuve, C., Stamenic, D., Fundamental & Clinical Pharmacology, 2017
  • Letter to the Editor: ESI-MS-MS library of 1,253 compounds for application in forensic and clinical toxicology, Marquet, Pierre, Sauvage, Francois-Ludovic, Analytical and Bioanalytical Chemistry, 2010, 10.1007/s00216-010-3451-z
  • New tools for cyclosporine dose optimization in thoracic transplant recipients, Stern, M., Rousseau, A., Marquet, P., Sebbag, L., Rolle, F., Reynaud-Gaubert, M., Redonnet, M., Pison, C., Knoop, C., Kessler, R., Guillemain, R., Estenne, M., Epailly, E., Premaud, A., Fruit, D., Fundamental & Clinical Pharmacology, 2011
  • Development of a Composite Endpoint (CEP) for Clinical Trials on Immunosuppressants (IS) in Lung Transplantation, Marquet, P., Estenne, M., Marin, B., Monchaud, C., Journal of Heart and Lung Transplantation, 2011
  • Recherche et innovation en santé : comment optimiser l’interface entre les startups/industries et les établissements de santé académiques ou non ?, , Therapie, 2019, 10.1016/j.therap.2019.11.006
  • Identification of Drug Metabolites Through Routine Application of a LC-MS/MS General Unknown Screening Procedure in Forensic Toxicology, Marquet, Pierre, Lachatre, Gerard, Gaulier, Jean-Michel, Saint-Marcoux, Franck, Picard, Nicolas, Sauvage, Francois-Ludovic, Therapeutic Drug Monitoring, 2009
  • Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients, Rousseau, Annick, Le Meur, Yann, Thiry, Philippe, Bernard, Nicole, Jacqz-Aigrain, Evelyne, Marquet, Pierre, Saint-Marcoux, Franck, Clinical Pharmacokinetics, 2006, 10.2165/00003088-200645090-00003
  • Joint modeling of longitudinal tacrolimus exposure in the first year post-LT and risk of renal failure: a new way to optimize target tacrolimus concentrations in the future, Premaud, Aurelie, Loustaud-Ratti, Veronique, Marquet, Pierre, Essig, Marie, Debette-Gratien, Maryline, Rousseau, Annick, Carrier, Paul, Hepatology, 2016
  • Preliminary evaluation of a nanoLC MALDI-Tof/Tof spectrometry method for the investigation of urine biomarkers of mdney allograft acute rejection, Gastinel, Louis N., Le Meur, Yannick, Marquet, Pierre, Benkali, Khaled, Therapeutic Drug Monitoring, 2007
  • Activity of the Calcineurin Pathway in Patients on the Liver Transplantation Waiting List: Factors of Variability and Response to Tacrolimus Inhibition, Marquet, P., Woillard, J. B., Gerona, S., Tourino, C., Vital, M., Lens, D., Esperon, P., Pouche, L., Noceti, O., Clinical Chemistry, 2017, 10.1373/clinchem.2017.272534
  • Falsely elevated whole-blood tacrolimus concentrations in a kidney-transplant patient: potential hazards, Kamar, Nassim, Saint-Marcoux, Franck, Lavit, Michel, Josse, Anne-Gaelle, Marquet, Pierre, Cointault, Olivier, Rostaing, Lionel, Transplant International, 2010, 10.1111/j.1432-2277.2009.00965.x
  • Predicting liver glucuronidation activities from heterologously expressed UDP-glucuronosyltransferases: application to morphine, Marquet, P., Gagez, A. L., Rouguieg-Malki, K., Sauvage, F. L., Chettouh, Z., Picard, N., Therapeutic Drug Monitoring, 2011
  • Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: Comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry, Marquet, P, Picard, N, Rousseau, A, Premaud, A, Therapeutic Drug Monitoring, 2006
  • In vitro comparison of the influence of the cyp 3A5*3 single nucleotide polymorphism on the hepatic clearance of three immunosuppressive drugs: everolimus, sirolimus and tacrolimus, Marquet, P., Sauvage, F. L., Comte, J. H., Djebli, N., Picard, N., Fundamental & Clinical Pharmacology, 2007
  • Automatic quantification of uracil and dihydrouracil in plasma., , Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2020, 10.1016/j.jchromb.2020.122038
  • CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients, Marquet, Pierre, Rerolle, Jean Philippe, Toupance, Olivier, Hoizey, Guillaume, Szelag, Jean-Christophe, Djebli, Nassim, Le Meur, Yannick, Clinical Pharmacology & Therapeutics, 2006, 10.1016/j.clpt.2006.03.012
  • The FcγRIIIA-158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T-cell-depleted kidney transplant recipients - a retrospective study., , Transplant international : official journal of the European Society for Organ Transplantation, 2020, 10.1111/tri.13624
  • Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants, Marquet, Pierre, Rousseau, Annick, Caillard, Sophie, Stojanova, Jana, Pharmacological Research, 2011, 10.1016/j.phrs.2010.10.016
  • Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches, Rousseau, A., Marquet, P., Urien, S., Oellerich, M., Armstrong, V. W., Toenshoff, B., Weber, L. T., Premaud, A., Pharmacological Research, 2011, 10.1016/j.phrs.2010.10.017
  • Quality control in therapeutic survey, Asqualab 1997-1999, Vassault, A, Roux, A, Marquet, P, Palette, C, Morel, I, Anglard, I, Feuillu, A, Annales De Biologie Clinique, 2000
  • Ganciclovir and its metabolites optimized pharmacokinetic modelling for exposure-effect in adult renal transplant recipients, Saint-Marcoux, F., Picard, N., Marquet, P., Essig, M., Sauvage, F. L., Woillard, J. B., Billat, P. A., Fundamental & Clinical Pharmacology, 2015
  • Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure - Reply, Marquet, Pierre, Rousseau, Annick, Alain, Sophie, Loustaud-Ratti, Veronique, Hepatology, 2008, 10.1002/hep.22454
  • Pharmacokinetic Modelling and Development of Bayesian Estimators for Therapeutic Drug Monitoring of Mycophenolate Mofetil in Reduced-Intensity Haematopoietic Stem Cell Transplantation, Marquet, Pierre, Kantelip, Jean-Pierre, Deconinck, Eric, Legrand, Faezeh, Larosa, Fabrice, Debord, Jean, Royer, Bernard, Saint-Marcoux, Franck, Clinical Pharmacokinetics, 2009
  • [Therapeutic drug monitoring]., Zahr, Noel, Verstuyft, Celine, Venisse, Nicolas, Urien, Saik, Turcant, Alain, Tribut, Olivier, Treluyer, Jean-Marc, Tittier, Karine, Taburet, Anne-Marie, Stanke-Labesque, Francoise, Simon, Nicolas, Sequier-Ubeaud, Genevieve, Sampol-Manos, Emmanuelle, Saivin, Sylvie, Saint-Marcoux, Franck, Royer-Morrot, Marie-Jose, Royer, Bernard, Rousseau, Annick, Poirier, Jean-Marie, Parant, Francois, Palette, Catherine, Paintaud, Gilles, Muret, Patrice, Monjanel-Mouterde, Suzanne, Monchaud, Caroline, Molimard, Mathieu, Mentre, France, Mathieu, Olivier, Marquet, Pierre, Loichot, Cecile, Libert, Frederic, Lemaire-Hurtel, Anne-Sophie, Lelong-Boulouard, Veronique, Lefeuvre, Sandrine, Laporte, Silvy, Lacarelle, Bruno, Jullien, Vincent, Jacqz-Aigrain, Evelyne, Hulot, Jean-Sebastien, Hulin, Anne, Hoizey, Guillaume, Hillaire-Buys, Dominique, Gozalo, Claire, Goirand, Francoise, Garraffo, Rodolphe, Gambier, Nicolas, Gagnieu, Marie-Claude, Furlan, Valerie, Fonrose, Xavier, Eschalier, Alain, Djerada, Zoubir, Diquet, Bertrand, Delhotal-Landes, Brigitte, Debruyne, Daniele, Dailly, Eric, Couet, William, Compagnon, Patricia, Comets, Emmanuelle, Chhun, Stephanie, Chatelut, Etienne, Camus, Maryse, Boyer, Jean-Christophe, Boulieu, Roselyne, Boulamery, Audrey, Bouchet, Stephane, Boisson, Mireille, Boisdron-Celle, Michele, Billaud, Eliane, Becquemont, Laurent, Basset, Thierry, Barrail-Tran, Aurelie, Alvarez, Jean-Claude, Abe, Emuri, groupe STP de la SFPT, Bentue-Ferrer, Daniele, Le Guellec, Chantal, Therapie, 2010
  • Relationship between exposure variability to calcineurin inhibitors over time and onset of infection in renal transplant patients, Monchaud, C., Marquet, P., Rousseau, A., Laroche, M. L., Bouchet, S., Gandia, P., Coubret, A., Villeneuve, C., Fundamental & Clinical Pharmacology, 2016
  • Perfusate Metabolomics Content and Expression of Tubular Transporters During Human Kidney Graft Preservation by Hypothermic Machine Perfusion., Barin-Le Guellec C, Marquet P, Bruyère F, Brichart N, Venhard JC, Arnion H, Nadal-Desbarats L, Miquelestorena-Standley E, Forestier L, Sauvage FL, Alarcan H, Faucher Q, Transplantation, 2022, 10.1097/tp.0000000000004129
  • Influence of sampling-time error on cyclosporine measurements nominally at 2 hours after administration, Marquet, P, Debord, J, Knoop, C, Estenne, M, Le Meur, Y, Rousseau, A, Saint-Marcoux, F, Clinical Chemistry, 2003, 10.1373/49.5.813
  • ASSOCIATION BETWEEN POLYMORPHISMS IN TARGET, METABOLISM OR TRANSPORT PROTEINS OF MYCOPHENOLATE SODIUM AND BPAR OR ADVERSE EVENTS IN RENAL TRANSPLANT PATIENTS, DOMINOS Study Grp, Marquet, Pierre, Touchard, Guy, Thierry, Antoine, Picard, Nicolas, Woillard, Jean-Baptiste, Transplant International, 2012
  • Identification of factors influencing mycophenolic acid area under the curve in systemic lupus erythematosus, Amoura, Z., Hulot, J. S., Piette, J. C., Funck-Brentano, C., Marquet, P., Haroche, J., Arnaud, L., Zahr, N., Fundamental & Clinical Pharmacology, 2010
  • Multicenter evaluation of a new inosine monophosphate dehydrogenase inhibition assay for quantification of total mycophenolic acid in plasma, Oellerich, Michael, Luthe, Hilmar, Streit, Frank, Domke, Ingrid, Coffing, Mary Jane, Schmitz, Gerd, Liebisch, Gerhard, Shaw, Leslie M., Marquet, Pierre, Brandhorst, Gunnar, Therapeutic Drug Monitoring, 2008
  • Bayesian estimation of mycophenolate mofetil (MMF) in lung transplantation using a population pharmacokinetic model developed in renal and lung transplant recipients, Rousseau, A., Marquet, P., Estenne, M., Knoop, C., Guillemain, R., Stern, M., Dromer, C., Reynaud-Gaubert, M., Kessler, R., Pison, C., Premaud, A., De Winter, B., Monchaud, C., Fundamental & Clinical Pharmacology, 2011
  • Pharmacogenetic determinants of aromatase inhibitors pharmacokinetics and side effects: 6-month results of the adjuvant breast cancer longitudinal PHACS study (NCT01127295), Evrard, A., Chatelut, E., Roche, H., Le Morvan, V., Mbatchi, L., Massoubre, A., Ellis, S., Levasseur, N., Despax, R., Solassol, I., Tafzi, N., Robert, J., White-Koning, M., Marquet, P., Pinguet, F., Thomas, F., Cancer Research, 2018
  • New Tools for Mycophenolate Mofetil (MMF) Dose Optimization in Lung Transplant Recipients during the First Year Post-Transplantation: The STIMMUGREP Trial, Marquet, P., Kessler, R., Estenne, M., Knoop, C., Guillemain, R., Stern, M., Reynaud-Gaubert, M., Pison, C., Monchaud, C., Journal of Heart and Lung Transplantation, 2011
  • Modelling ciclosporin double-peak absorption profiles in,the early post-transplantation period, Marquet, P, Rousseau, A, Clinical Pharmacokinetics, 2004, 10.2165/00003088-200443140-00007
  • CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation, Marquet, P, Legendre, C, Daly, A, Beaune, P, Tregouet, D, Laurent-Puig, P, Buchler, M, Touchard, G, Le Meur, Y, De Ligny, BH, Etienne, I, Thervet, E, Anglicheau, D, Clinical Pharmacology & Therapeutics, 2004, 10.1016/j.clpt.2004.01.009
  • Perfusate metabolomics content and tubular transporters expression during kidney graft preservation by hypothermic machine perfusion, Guellec CB, Marquet P, Bruyère F, Brichart N, Venhard J, Arnion H, Nadal-Desbarats L, Miquelestorena-Standley E, Forestier L, Sauvage F, Alarcan H, Faucher Q, 2021, 10.1101/2021.09.27.21264167
  • Population pharmacokinetic of gentamicin in hemodialysis patients: modeling, simulations and recommendations, Woillard, J. B., Marquet, P., Saint-Marcoux, F., Monchaud, C., Allot, V., Franck, B., Fundamental & Clinical Pharmacology, 2018
  • [Pharmacogenetics and immunosuppressor drugs: impact and clinical interest in transplantation]., Picard, N, Djebli, N, Marquet, P, Annales pharmaceutiques francaises, 2007, 10.1016/S0003-4509(07)74197-4
  • Cyclosporine A inhibits MRTF-SRF signalling through Na+/K+ ATPase inhibition & Actin remodelling, Essig M, Marquet P, Sauvage F, Di Meo F, Arnion H, Čechová P, Faucher Q, Burat B, 2018, 10.1101/492843
  • Determination of trimeprazine and its main metabolites in mouse serum and thyroid by liquid chromatography electrospray mass spectrometry, Lachatre, G, Raby, C, Buxeraud, J, Rousseau, A, Marquet, P, Sauvage, MF, Journal of Liquid Chromatography & Related Technologies, 1998, 10.1080/10826079808001266
  • Relative quantitative proteomic analysis of CNI-induced toxicity in a porcine proximal tubule cell line using iTRAQ technique, Essig, Marie, Marquet, Pierre, Gonzalez, Julien, Pinault, Emilie, Burat, Bastien, Acta Physiologica, 2016
  • QuEChERS sample preparation prior to LC-MS/MS determination of opiates, amphetamines, and cocaine metabolites in whole blood, Saint-Marcoux, Franck, Marquet, Pierre, Gaulier, Jean-Michel, Poncelet, Lauranne, El Balkhi, Souleiman, Dulaurent, Sylvain, Analytical and Bioanalytical Chemistry, 2016, 10.1007/s00216-015-9248-3
  • Proceedings of the 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Marquet, Pierre, Therapeutic Drug Monitoring, 2008
  • Design of maximum a posteriori (MAP) Bayesian estimators for oral cyclosporin pharmacokinetics forecasting in de novo renal transplant patients, Marquet, P, Hoizey, G, Toupance, O, Le Meur, Y, Rousseau, A, Debord, J, Saint-Marcoux, F, Therapeutic Drug Monitoring, 2003
  • The Hepatic Organic Anion Transporting Polypeptides (OATP) Uptake Transporters are Involved in Mycophenolic Acid Pharmacokinetics: Effect of Major Genetic Variants on Drug Exposure in Kidney Transplants, Marquet, P., Giacomini, K. M., Le Meur, Y., Lebranchu, Y., Woillard, J-B., Yee, S. W., Picard, N., Therapeutic Drug Monitoring, 2009
  • Limited sampling strategy for the estimation of mycophenolate AUC: A large scale study, Marquet, P, Rousseau, A, Le Meur, Y, Premaud, A, Therapeutic Drug Monitoring, 2003
  • Ribavirin pharmacokinetic study will lead to individual dose adjustment in chronic hepatitis C patients, Vidal, E, Liozon, E, Lefebvre, A, Lunel, F, Denis, F, Marquet, P, Lemonnier, L, Alain, S, Loustaud-Ratti, V, Hepatology, 2004
  • Anti-hepatitis C virus drugs and kidney, Loustaud-Ratti, V., Jacques, J., Marquet, P., Rousseau, A., Sautereau, D., Debette-Gratien, M., Essig, M., Carrier, P., World Journal of Hepatology, 2016, 10.4254/wjh.v8.i32.1343
  • Improvement of Charcot-Marie-Tooth Phenotype with a Nanocomplex Treatment in Two Transgenic Models of CMT1A, Massry ME, Sturtz F, Sol V, Vallat J, Favreau F, Marquet P, Bregier F, Faye P, Pinault E, Richard L, Vignaud L, Masri TE, Ndong-Ntoutoume GM, Msheik Z, 2023, 10.21203/rs.3.rs-2786317/v1
  • [Summary of the recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) on the therapeutic drug monitoring of tacrolimus]., , Therapie, 2020, 10.1016/j.therap.2020.06.004
  • Population pharmacokinetics of gentamicin in haemodialysis patients: modelling, simulations and recommendations., , European journal of clinical pharmacology, 2020, 10.1007/s00228-020-02867-3
  • HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents, Loustaud-Ratti, Veronique, Essig, Marie, Sautereau, Denis, Alain, Sophie, Marquet, Pierre, Mesturoux, Laura, Abraham, Julie, Debette-Gratien, Marilyne, Tabouret, Tessa, Jacques, Jeremie, Jaccard, Arnaud, Carrier, Paul, Liver International, 2015, 10.1111/liv.12897
  • Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients, Lachatre, G, Merle, L, Carpentier, N, Debord, J, Marquet, P, Sabot, C, European Journal of Clinical Pharmacology, 1998, 10.1007/s002280050441
  • Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part II, Marquet, Pierre, Monchaud, Caroline, Clinical Pharmacokinetics, 2009
  • Dexamethasone in resting and exercising men. II. Effects on adrenocortical hormones, Galen, FX, Chassain, AP, Marquet, P, Lac, G, Journal of Applied Physiology, 1999
  • Cyclosporine A (CsA): new perspectives for an old molecule, Marquet, P., Fundamental & Clinical Pharmacology, 2001
  • Mycophenolate mofetil monitoring in kidney transplant recipients: A cost-effectiveness study, Le Meur, Y., Jacqz-Aigrain, E., Saivin, S., Debruyne, D., Turcant, A., Grima, M., Venisse, N., Hary, L., Compagnon, P., Hoizey, G., Vergnenegre, A., Marquet, P., Laroche, M. L., Therapeutic Drug Monitoring, 2007
  • Cyclosporine monitoring in renal transplant recipients with induction therapy: C-2 levels in patients monitored on C-0, French Pharmacological Soc, Marquet, P, Simon, N, Peytavin, G, Paintaud, G, Kergueris, MF, Boulieu, R, Bonardet, A, Bernard, N, Bentue-Ferrer, D, Loichot, C, Fundamental & Clinical Pharmacology, 2006, 10.1111/j.1472-8206.2005.00383.x
  • Metabolic alterations of uterine grafts after extended cold ischemic storage: experimental study in ewes., , Molecular human reproduction, 2019, 10.1093/molehr/gaz041
  • Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients, Cassuto, E., Thervet, E., Charpentier, B., Buchler, M., Gatault, P., Sakarovitch, C., Kamar, N., Rostaing, L., Woillard, J. B., Albano, L., Marquet, P., Pharmacological Research, 2018, 10.1016/j.phrs.2017.12.005
  • Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects: results of a French collaborative study, Pourrat, O, Tilhet-Coart, S, Moulsma, M, Nouveau, J, Goulle, JP, Kaddour, A, Vincent, F, Martin-Dupont, S, Marquet, P, Ludes, B, Gaulier, JM, Kintz, P, Mura, P, Forensic Science International, 2003, 10.1016/S0379-0738(03)00052-5
  • Pharmacokinetic modelling of raltegravir in HIV patients, Clementi, E., Marquet, P., Baldelli, S., Parinaud, A. S., Cattaneo, D., Saint-Marcoux, F., Therapeutic Drug Monitoring, 2011
  • In silico pharmacology: Drug membrane partitioning and crossing, Trouillas, Patrick, Otyepka, Michal, Marquet, Pierre, Paloncyova, Marketa, Chantemargue, Benjamin, Ossman, Tahani, Berka, Karel, Fabre, Gabin, Di Meo, Florent, Pharmacological Research, 2016, 10.1016/j.phrs.2016.06.030
  • Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation, Jean‐Baptiste Woillard, Philippe Ovetchkine, Pierre Marquet, Julie Autmizguine, Bénédicte Franck, Clinical Pharmacology & Therapeutics, 2022, 10.1002/cpt.2431
  • Foreseeable advantages and limits of buprenorphine-naloxone association, Marquet, P, Kintz, P, Gatignol, C, Barjhoux, CE, Villier, C, Dematteis, M, Mallaret, M, Buprenorphine Therapy of Opiate Addiction, 2002
  • PK Modelling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving Once-Daily Tacrolimus (ADVAGRAF)., Marquet, Pierre, Undre, Nasrullah, Debord, Jean, Saint-Marcoux, Franck, American Journal of Transplantation, 2009
  • Relationship between psychotropic drugs and thyroid function: A review, Lachatre, G, Buxeraud, J, Raby, C, Rousseau, A, Marquet, P, Sauvage, MF, Toxicology and Applied Pharmacology, 1998, 10.1006/taap.1998.8367
  • Clinical and in-vitro study of the pharmacokinetic interactions of cyclosporin and sirolimus with mycophenolate mofetil., Rousseau, A, Szelag, JC, Toupance, O, Le Meur, Y, Hoizey, G, Picard, N, Marquet, P, American Journal of Transplantation, 2005
  • Maximum A posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods, Marquet, P, Toiipance, O, Hoizey, G, Rousseau, A, Szelag, JC, Debord, J, Le Meur, Y, Premaud, A, Therapeutic Drug Monitoring, 2005
  • Decrease of serum paraoxonase activity with age and in chronic renal failure: Relationship with coronary heart disease, Leroux-Robert, C, Merle, L, Lachatre, G, Marquet, P, Charmes, JP, Debord, J, Dantoine, TF, Circulation, 1998
  • Killing two birds with one stone: a population pharmacokinetic model for two tacrolimus formulations, Marquet, P., Rostaing, L., Rousseau, A., Kamar, N., de Winter, B. C. M., Woillard, J. B., Therapeutic Drug Monitoring, 2011
  • Epigenetic research in pharmacology: perspectives and pitfalls, Picard, N., Marquet, P., Gonzalez, J., Pouche, L., Lebreton, V., Fundamental & Clinical Pharmacology, 2015
  • Buprenorphine and pregnancy - A comparative, multicenter clinical study of high-dose buprenorphine vs methadone maintenance, Marquet, P, Kintz, P, Piquet, M, Cneude, F, Simmat-Durand, L, Aubisson, S, Lejeune, C, Buprenorphine Therapy of Opiate Addiction, 2002
  • Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation, Rousseau, Annick, Marquet, Pierre, Guillemain, Romain, Kessler, Romain, Stern, Marc, Pison, Christophe, Reynaud-Gaubert, Martine, Estenne, Marc, Knoop, Christiane, de Winter, Brenda C., Monchaud, Caroline, Clinical Pharmacokinetics, 2012
  • Multi-omics investigation of tacrolimus nephrotoxicity, Essig M, Marquet P, Arnion H, Barrot C, Pinault E, Sauvage F, Aouad H, Faucher Q, 2021, 10.1101/2021.07.29.454229
  • BLOOD LACTATE LEVELS IN THE RACE HORSE - SEQUENCES OF INCREMENTAL AND CONSTANT-LOAD SHORT-TERM RUNS, VALADE, M, DALMAY, F, MARQUET, P, VILLENEUVE, P, NICOLAS, A, ANTONINI, MT, BLANC, P, DAURIAC, E, CHASSAIN, AP, Archives Internationales De Physiologie De Biochimie Et De Biophysique, 1992, 10.3109/13813459209000728
  • Buprehorphine as a viable pharmacotherapy is Australia, Marquet, P, Kintz, P, Lewis, JH, Buprenorphine Therapy of Opiate Addiction, 2002
  • Simultaneous determination of six dialkylphosphates in urine by liquid chromatography tandem mass spectrometry, Lachatre, G, Marquet, P, Saint-Marcoux, F, Dulaurent, S, Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 2006, 10.1016/j.jchromb.2005.12.012
  • Uterus human leucocyte antigen expression in the perspective of transplantation., Drouet M, Marquet P, Aubard Y, Piver P, Pacha AF, Bibes R, Essig M, Guillaudeau A, Filloux M, Gauthier T, The journal of obstetrics and gynaecology research, 2016, 10.1111/jog.13107
  • Insights into the structure and function of the human organic anion transporter 1 in lipid bilayer membranes, Florent Di Meo, Pierre Marquet, Chantal Barin-Le Guellec, Benjamin Chantemargue, Marving Martin, Quentin Faucher, Ágota Tóth, Angelika Janaszkiewicz, 2022, 10.1101/2022.01.10.475390
  • Therapeutic drug monitoring: Analytical, pharmacokinetic and clinical aspects, Marquet, P, Acta Clinica Belgica, 1999
  • Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation., Naesens M, Noël LH, Sprangers B, Kuypers D, Thorrez L, Thaunat O, Koenig A, Saison C, Heylen L, Wevers M, de Loor H, Lerut E, Gazut S, Callemeyn J, Yazdani S, Kidney international, 2018, 10.1016/j.kint.2018.08.027
  • Population Pharmacokinetics (popPK) of Capecitabine in Elderly Patients With Colorectal or Breast Cancer, Tubiana-Mathieu, N., Rousseau, A., Marquet, P., Woillard, J. B., Leobon, S., Martin, J., Urien, S., Sauvage, F. L., Lavau-Denes, S., Abdi, Z. Daher, Therapeutic Drug Monitoring, 2013
  • Pharmacology of high-dose buprenorphine, Kintz, P, Marquet, P, Buprenorphine Therapy of Opiate Addiction, 2002
  • Antibody-mediated rejection with and without donor-specific anti-human leucocyte antigen antibodies: performance of the peripheral blood 8-gene expression assay., , Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2020, 10.1093/ndt/gfaa096
  • Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs, Meyer, Eric J., Marquet, Pierre, Renjen, Varun, van Gelder, Teun, Wallemacq, Pierre, Clarke, William, Langman, Loralie J., Vinks, Alexander A., Christians, Uwe, Therapeutic Drug Monitoring, 2015, 10.1097/FTD.0000000000000205
  • Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin, RIBAJUSTE Group, Trepo, Christian, Marquet, Pierre, Zublena, Iresne, Picard, Nicolas, Lunel-Fabiani, Francoise, Silvain, Christine, Dao, Thong, Tran, Albert, Gagnieu, Marie-Claude, Deny, Paul, Alain, Sophie, Rousseau, Annick, Pradat, Pierre, Thevenon, Sylvie, Maynard, Marianne, Loustaud-Ratti, Veronique, Therapeutic Drug Monitoring, 2016, 10.1097/FTD.0000000000000332
  • A soldier who had seizures after drinking quarter of a litre of wine, Lachatre, G, Vignon, P, Francois, B, Marquet, P, Lancet, 1996, 10.1016/S0140-6736(96)05459-1
  • Fully automated sample preparation procedure to measure drugs of abuse in plasma by liquid chromatography tandem mass spectrometry, Saint-Marcoux, F., El Balkhi, S., Marquet, P., Moreau, S., Baumgarten, S., Loftus, N., Dulaurent, S., Barnes, A., Robin, T., Analytical and Bioanalytical Chemistry, 2018, 10.1007/s00216-018-1159-7
  • UTERUS TOLERANCE TO LONG-TIME COLD ISCHEMIC STORAGE AFTER AUTO-TRANSPLANTATION IN EWE, Gauthier, T., Piccardo, A., Marquet, P., Terro, F., Yardin, C., Couquet, C., Lachatre, D., Mesturoux, L., Tholance, Y., Ponsonnard, S., Tricard, J., Transplant International, 2016
  • Polymorphisms of the mammalian target of rapamycin (mTOR) and gene expression in the lymphocytes of healthy volunteers, Marquet, P., Soudan, M. C., Woillard, J. B., Picard, N., Fundamental & Clinical Pharmacology, 2010
  • Investigation of the intestinal absorption of immunosuppressive drugs using the human intestinal Caco-2 cell line, Marquet, P., Beneytout, J. L., Liagre, B., Picard, N., Boussera, B., Fundamental & Clinical Pharmacology, 2007
  • Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: Pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients, Marquet, P., Jacqz-Aigrain, E., Saivin, S., Debruyne, D., Hary, L., Compagnon, P., Hoizey, G., Turcant, A., Loichot, C., Venisse, N., Le Meur, Y., Rousseau, A., Premaud, A., Pharmacological Research, 2010, 10.1016/j.phrs.2009.09.006
  • Bayesian estimation of methotrexate pharmacokinetic parameters and area under the curve in children and young adults with localised osteosarcoma, Marquet, P, Lachatre, G, Debord, J, Delephine, G, Delephine, N, Sabot, C, Rousseau, A, Clinical Pharmacokinetics, 2002, 10.2165/00003088-200241130-00006
  • Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C, Vidal, Elisabeth, Liozon, Eric, Fauchais, Anne-Laure, Lefebvre, Annie, Cales, Paul, Lunel, Francoise, Denis, Francois, Marquet, Pierre, Sauvage, Francois Ludovic, Hubert, Isabelle Fouchard, Rousseau, Annick, Alain, Sophie, Loustaud-Ratti, Veronique, Hepatology, 2008, 10.1002/hep.22217
  • Mycophenolate exposure variability in the long term and influence of cyclosporine dose reduction in stable renal transplant recipients., Rousseau, Annick, Debruyne, Daniele, Paintaud, Gilles, Venisse, Nicolas, Hoizey, Guillaume, Saint-Marcoux, Franck, Etienne, Isabelle, Marquet, Pierre, American Journal of Transplantation, 2007
  • AADAPT-Analysis of Advagraf Dose Adaptation Post Transplantation, Marquet, P., Thervet, E., Charpentier, B., Lebranchu, Y., Rostaing, L., Cassuto, E., Albano, L., American Journal of Transplantation, 2014
  • Early dose adjustment of RBV in HCV patients treated with peginterferon and RBV is efficient and safe in the population underexposed to the drug. Multicentric French Study (Ribajuste), Trepo, Christian, Marquet, Pierre, Zublena, Irene, Picard, Nicolas, Lunel-Fabiani, Francoise, Deny, Paul, Alain, Sophie, Gagnieu, Marie-Claude, Rousseau, Annick, Pradat, Pierre, Thevenon, Sylvie, Maynard-Muet, Marianne, Loustaud-Ratti, Veronique, Hepatology, 2015
  • Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation, Elens, L., Haufroid, V., Marquet, P., Hesselink, D. A., Lloberas, N., van Gelder, T., van Schaik, R. H., Capron, A., Neely, M., Mourad, M., Woillard, J. B., Frontiers in Pharmacology, 2017, 10.3389/fphar.2017.00358
  • FP7 BIOMARGIN SHOWS THAT SMALL SETS OF INTRA-GRAFT MICRORNAS ARE STRONGLY ASSOCIATED WITH RENAL ALLOGRAFT LESIONS, Anglicheau, D., Marquet, P., Essig, M., Gwinner, W., Naesens, M., Gazut, S., Benon, A., Tinel, C., Transplant International, 2018
  • Pharmacokinetics of cyclosporine and development of a Bayesian estimator in heart, lung and renal transplant patients: A Nonmem analysis, Rousseau, A, Marquet, P, Saint-Marcoux, F, Therapeutic Drug Monitoring, 2005
  • Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies, Marquet, P, Estenne, M, Rousseau, A, Thiry, P, Debord, J, Knoop, C, Saint-Marcoux, F, Clinical Pharmacokinetics, 2005, 10.2165/00003088-200544120-00010
  • Steroid-free regimen and optimization of mycophenolic acid (MPA) exposure in liver transplant recipients: final results of a randomized multicenter trial, Rostaing, Lionel, Tagieva, Naila, Duer, Carole, Sebagh, Mylene, Marquet, Pierre, Vanlemmens, Claire, Hardwigsen, Jean, Dharancy, Sebastien, Pageaux, Georges-Philippe, Duvoux, Christophe, Altieri, Mario, Calmus, Yvon, Neau-Cransac, Martine, Leroy, Vincent, Radenne, Sylvie, Gugenheim, Jean, Durand, Francois, Saliba, Faouzi, Hepatology, 2012
  • Interaction of everolimus and sirolimus with the hepatic and intestinal Organic Anion Transporting Polypeptides (OATPs), Marquet, P., Giacomini, K. M., Yee, S. W., Lamoureux, F., Levoir, L., Picard, N., Fundamental & Clinical Pharmacology, 2010
  • The European Association for Clinical Pharmacology and Therapeutics—25 years’ young and going strong, , European Journal of Clinical Pharmacology, 2019, 10.1007/s00228-019-02690-5
  • Tacrolimus (Tac) Pharmacokinetics (PK) in Cystic Fibrosis (CF) and Non-CF Lung Transplant Recipients: Preliminary Results of the STIMMUGREP Trial., Marquet, Pierre, Rousseau, Annick, Guillemain, Romain, Dromer, Claire, Kessler, Romain, Stern, Marc, Pison, Christophe, Reynaud-Gaubert, Martine, Monchaud, Caroline, Estenne, Marc, American Journal of Transplantation, 2009
  • Population pharmacokinetics of amikacin in geriatric patients studied with the NPEM-2 algorithm, Lachatre, G, Merle, L, Marquet, P, Charmes, JP, Debord, J, International Journal of Clinical Pharmacology and Therapeutics, 1997
  • Influence of MRP2 Haplotype on MPA Exposure in Kidney Transplant Patients, Picard, N., Marquet, P., Rousseau, A., Levoir, L., Woillard, J. B., Therapeutic Drug Monitoring, 2009
  • Sensitive microanalysis of imipramine and desipramine in single rat thyroids by gas chromatography mass spectrometry, Lachatre, G, Raby, C, Buxeraud, J, Comby, F, Marquet, P, Rousseau, A, Journal of Chromatography B, 1997, 10.1016/S0378-4347(97)00052-2
  • Therapeutic Drug Monitoring in the Era of Precision Medicine: Achievements, Gaps, and Perspectives-An Interview in Honor of Professor Charles Pippenger., Shipkova M, Vinks AA, Walson P, Bergan S, Svinarov D, Cattaneo D, Marquet P, Wong SH, Therapeutic drug monitoring, 2021, 10.1097/ftd.0000000000000932
  • Phenotyping of Uracil and 5-Fluorouracil Metabolism Using LC-MS/MS for Prevention of Toxicity and Dose Adjustment of Fluoropyrimidines., , Therapeutic drug monitoring, 2020, 10.1097/ftd.0000000000000768
  • Co-Medication with Cyclosporine and the UDP-Glucuronosyltransferase (UGT) 1A8*2 Allele Are Associated with a Decreased Risk of Mycophenolate Mofetil Related Diarrhea in Renal Transplant Patients., Le Meur, Yann, Marquet, Pierre, Drouet, Mireille, Rousseau, Annick, Picard, Nicolas, Woillard, Jean-Baptiste, Rerolle, Jean-Philippe, American Journal of Transplantation, 2009
  • Buprenorphine maintenance treatment in primary care - An overview of the French experience and insight into the prison setting, Kintz, P, Marquet, P, Vignau, J, Deveaux, M, Buprenorphine Therapy of Opiate Addiction, 2002
  • Endogenous metabolites-mediated communication between OAT1/OAT3 and OATP1B1 may explain the association between SLCO1B1 SNPs and methotrexate toxicity, Andres, C., Marquet, P., Gyan, E., Choquet, S., Berthelot, A., Woillard, J. B., Martinez, D., Muhrez, K., Barin-Le Guellec, C., Fundamental & Clinical Pharmacology, 2018
  • Population pharmacokinetics and Bayesian estimator of cyclosporine in pediatric renal transplant patients, Jacqz-Aigrain, E., Marquet, P., Leroy, V., Zhang, D., Rousseau, A., Saint-Marcoux, F., Irtan, S., Therapeutic Drug Monitoring, 2007, 10.1097/FTD.0b013e3180310f9d
  • Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration Data., Aouam, Karim, Saint-Marcoux, Franck, Marquet, Pierre, Boughattas, Naceur, Chaabane, Amel, Debord, Jean, Woillard, Jean Baptiste, Ben Fredj, Nadia, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2016
  • [Molecular pharmacogenetics in hospital laboratories in France: current data and future prospects]., Verstuyft, C, Watier, H, Picard, N, Peoc'h, K, Paintaud, G, Namour, B, Morel, A, Marquet, P, Loriot, M-A, Loric, S, Jacqz-Aigrain, E, Goze, C, Gamelin, E, Gagnieu, M-C, Fonrose, X, Dhaneens, C-M, Broly, F, Boyer, J-C, Boisdron-Celle, M, Bezieau, S, Bessard, G, Becquemont, L, Beaune, P-H, Allorge, D, Annales pharmaceutiques francaises, 2007, 10.1016/S0003-4509(07)74196-2
  • COUNTERPOINT - Is Pharmacokinetic or Pharmacodynamic Monitoring of Calcineurin Inhibition Therapy Necessary?, Marquet, Pierre, Clinical Chemistry, 2010, 10.1373/clinchem.2009.138693
  • Pharmacokinetic modelling and development of Bayesian estimators for the therapeutic drug monitoring of Mycophenolate mofetil in non myeloablative haematopoietic cell transplantation, Marquet, P., Deconinck, E., Legrand, F., Larosa, F., Debord, J., Royer, B., Saini-Marcoux, F., Fundamental & Clinical Pharmacology, 2008
  • FP7 BIOMARGIN SHOWS THAT A SMALL SET OF BLOOD MICRO-RNAS IS ASSOCIATED WITH ACUTE KIDNEY ALLOGRAFTS REJECTION, Anglicheau, D., Marquet, P., Essig, M., Gwinner, W., Naesens, M., Gazut, S., Benon, A., Tinel, C., Transplant International, 2018
  • Evaluating Patients' Experiences Towards Their Immunosuppressive Treatment: A Way to Improve Adherence, Monchaud, C., Marquet, P., Zoughbi, J., Hegarat, S., Essig, M., Grau, M., Villeneuve, C., American Journal of Transplantation, 2017
  • Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy, Paintaud, G, Marquet, P, Lebranchu, Y, Gakoue, JE, Le Meur, Y, Giraudeau, B, Buchler, M, Le Guellec, C, European Journal of Clinical Pharmacology, 2002, 10.1007/s00228-001-0389-2
  • Liquid chromatography-tandem mass spectrometry for detection of low concentrations of 21 benzodiazepines, metabolites, and analogs in urine: Method with forensic applications, Marquet, Pierre, Lachatre, Gerard, Gaulier, Jean-Michel, Charvier, Fabienne, Sauvage, Francois-Ludovic, Quintela, Oscar, Clinical Chemistry, 2006, 10.1373/clinchem.2005.065631
  • The apoptosis-inducing toxin Brefeldin A is taken up and secondarily released by neurons, Hugon, J, Esclaire, F, Marquet, P, Terro, F, Yardin, C, Neuroscience Research Communications, 2000, 10.1002/1520-6769(200009/10)27:2<125::AID-NRC6>3.0.CO;2-0
  • Low mycophenolic acid area under the curve is associated with increased systemic lupus erythematosus activity, Amoura, Z., Lechat, P., Piette, J. C., Marquet, P., Cacoub, P., Costedoat-Chalumeau, N., Debord, J., Haroche, J., Hulot, J. S., Zahr, N., Fundamental & Clinical Pharmacology, 2008
  • Optimized population pharmacokinetic model of cyclosporin in stable renal transplant patients., Marquet, P, Buchler, M, Le Meur, Y, Debord, J, Saint-Marcoux, F, Leger, F, Rousseau, A, Therapeutic Drug Monitoring, 2003
  • Mycophenolic acid exposure prediction using machine learning., , Clinical pharmacology and therapeutics, 2021, 10.1002/cpt.2216
  • Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference, Mourad, Michel, Westley, Ian S., Weber, Lutz T., Undre, Nas, Toenshoff, Burkhand, Thervet, Eric, Oellerich, Michael, Marquet, Pierre, Le Meur, Yannick, Kuypers, Dirk, Johnston, Atholl, Holt, David W., Haufroid, Vincent, Brunet, Merce, Armstrong, Victor W., Wallemacq, Pierre, Therapeutic Drug Monitoring, 2009
  • Determination of LSD and N-demethyl-LSD in urine by liquid chromatography coupled to electrospray ionization mass spectrometry, Lachatre, G, Dupuy, JL, Lotfi, H, Verneuil, B, Marquet, P, Hoja, H, Journal of Chromatography B, 1997, 10.1016/S0378-4347(97)00008-X
  • Rheumatoid factor interference in a tacrolimus immunoassay., Fortuny Marques, Regina, Riesco Prieto, Maria, Barcelo Bennasar, Antonia, Castanyer Puig, Bartomeu, Ferrer, Joana Maria, Marquet, Pierre, Barcelo Martin, Bernardi, Therapeutic drug monitoring, 2009, 10.1097/FTD.0b013e3181c01da1
  • Mycophenolic Acid Area Under the Curve Correlates With Disease Activity in Lupus Patients Treated With Mycophenolate Mofetil, Amoura, Zahir, Piette, Jean-Charles, Funck-Brentano, Christian, Hulot, Jean-Sebastien, Costedoat-Chalumeau, Nathalie, Haroche, Julien, Marquet, Pierre, Arnaud, Laurent, Zahr, Noel, Arthritis and Rheumatism, 2010, 10.1002/art.27495
  • Comparison of a preliminary procedure for the general unknown screening of drugs and toxic compounds using a quadrupole-linear ion-trap mass spectrometer with a liquid chromatography-mass spectrometry reference technique, Leblanc, JCY, Gamble, TN, Saint-Marcoux, F, Marquet, P, Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 2003, 10.1016/S1570-0232(03)00071-0
  • Immunosuppressant quantification in intravenous microdialysate - towards novel quasi-continuous therapeutic drug monitoring in transplanted patients., , Clinical chemistry and laboratory medicine, 2020, 10.1515/cclm-2020-1542
  • Effects of Ischemia-Reperfusion on Tubular Cell Membrane Transporters and Consequences in Kidney Transplantation., , Journal of clinical medicine, 2020, 10.3390/jcm9082610
  • Cytochrome P450 3A5 polymorphism significantly influences sirolimus oral clearance in de novo renal transplant recipients without calcineurin inhibitors, Marquet, P, Rousseau, A, Hoizey, G, Toupance, O, Le Meury, Y, Djebli, N, Therapeutic Drug Monitoring, 2005, 10.1097/00007691-200504000-00155
  • Tacrolimus population pharmacokinetics analysis and Bayesian estimation in renal transplant recipients, Rousseau, A., Marquet, P., Turcant, A., Villemain, F., Toupance, O., Hoizey, G., Rerolle, J. P., Picard, N., Premaud, A., Le Meur, Y., Benkali, K., Fundamental & Clinical Pharmacology, 2009
  • Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography mass spectrometry with electrospray ionization, Lachatre, G, Penicaut, B, Dupuy, JL, Lotfi, H, Verneuil, B, Marquet, P, Hoja, H, Journal of Chromatography B, 1997, 10.1016/S0378-4347(96)00294-0
  • Comment le programme d’investissements d’avenir a-t-il stimulé la recherche et l’innovation en santé ?, Zins M, Mahfoudi A, Lyonnet S, Garbil B, Froguel P, Duluc G, Debette S, Boitard C, Beretz A, Benhabiles N, Le Jeunne C, Vacaresse E, Dantonel JC, Bordet R, Therapie, 2022, 10.1016/j.therap.2022.01.005
  • Development of a Population Pharmacokinetic model and a Bayesian Estimator for estimation of Everolimus Whole Blood and Intra-lymphocyte Exposure in Renal Transplant Recipients, Robertsen, I., Marquet, P., Asberg, A., Debord, J., Woillard, J. B., Fundamental & Clinical Pharmacology, 2018
  • Insights into the structure and function of the human organic anion transporter 1 in lipid bilayer membranes., Di Meo F, Marquet P, Barin-Le Guellec C, Chantemargue B, Martin M, Faucher Q, Tóth Á, Janaszkiewicz A, Scientific reports, 2022, 10.1038/s41598-022-10755-2
  • Towards therapeutic drug monitoring of mycophenolic acid in cicatricial pemphigoid patients, Bedane, C., Marquet, P., Assikar, S., Saint-Marcoux, F., Monchaud, C., Roussel, H., Maffioletti, P. F., Woillard, J. B., Fundamental & Clinical Pharmacology, 2017
  • In vitro LC-MS/MS cocktail strategy for the simultaneous evaluation of glucuronidation enzyme activities of human liver microsomes, Marquet, P., Sauvage, F. L., Picard, N., Rouguieg, K., Fundamental & Clinical Pharmacology, 2009
  • Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?, Hellemans R, Abramowicz D, Massart A, Monchaud C, Marquet P, Wouters K, Roosens L, Haverals L, Transplantation direct, 2023, 10.1097/txd.0000000000001439
  • Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry, Lachatre, G, Dupuy, JL, Gaulier, JM, Lacassie, E, Rousseau, A, Lachatre, F, Marquet, P, Ragot, S, Journal of Chromatography B, 1999, 10.1016/S0378-4347(99)00452-1
  • Ex-vivo pharmacodynamics of tacrolimus on the calcineurin pathway of lymphocytes from healthy donors, Marquet, P., Esperon, P., Boumediene, A., Taupin, J. L., Noceti, O., Fundamental & Clinical Pharmacology, 2012
  • Treatment of requests of dosages of pesticides in biological environments : some problems encountered frequently, Lachatre, G, Marquet, P, Gaulier, JM, Dulaurent, S, Acta Clinica Belgica, 2006
  • Urinary collagen-derived peptides as sensitive markers for bone resorption and bisphosphonate treatment in kidney transplant patients, Metzger J, Gwinner W, Perrin P, Marquet P, Prié D, Bienaimé F, Latosinska A, Pejchinowski M, Mischak H, Kochman A, Moulin B, Caillard S, Anglicheau D, Marx D, 2022, 10.1101/2022.02.15.22270979
  • Integrative Omics Analysis Unravels Microvascular Inflammation-Related Pathways in Kidney Allograft Biopsies., Anglicheau D, Naesens M, Marquet P, Gwinner W, Rabant M, Aouni L, Morin L, Sauvaget V, Van Loon E, Callemeyn J, Lamarthée B, Tinel C, Frontiers in immunology, 2021, 10.3389/fimmu.2021.738795
  • Tacrolimus Bayesian dose adjustment in pediatric renal transplant recipients., , Therapeutic drug monitoring, 2020, 10.1097/ftd.0000000000000828
  • General unknown screening procedure for the characterization of human drug metabolites: Application to loratadine phase I metabolism, Marquet, Pierre, Boughaftas, Naceur A., Sauvage, Francois-Ludovic, Dridi, Dorra, Picard, Nicolas, Journal of Separation Science, 2009, 10.1002/jssc.200900099
  • Liquid chromatography-mass spectrometry: potential in forensic and clinical toxicology, Lachatre, G, Marquet, P, Journal of Chromatography B, 1999, 10.1016/S0378-4347(99)00147-4
  • Overview of accessibility and quality of antiepileptic drugs in Madagascar, Ratsimbazafy, Voa, Preux, Pierre-Marie, Marquet, Pierre, Solofomalala, Gaetan Duval, Megherbi, Mehdi, Andriambololona, Rindra, Tanamasoandro, Rakotovao, Jost, Jeremy, Nizard, Mandy, Seizure-European Journal of Epilepsy, 2016, 10.1016/j.seizure.2016.07.015
  • FP7 BIOMARGIN SHOWS THAT SMALL SETS OF URINARY PEPTIDES ARE GOOD BIOMARKERS OF ACUTE KIDNEY GRAFT REJECTION, Marquet, P., Essig, M., Mihatsch, M., Brocheriou, I., Noel, L. H., Gwinner, W., Anglicheau, D., Naesens, M., Woillard, J. B., Sauvage, F. L., Transplant International, 2017
  • A non-fatal case of intoxication with foxglove, documented by means of liquid chromatography-electrospray-mass spectrometry, Lachatre, G, Gaulier, JM, Martin-Dupont, S, Marquet, P, Lacassie, E, Journal of Forensic Sciences, 2000
  • Adherence Time-Profiles of Renal Transplant Patients During the Three First Years Post-Transplantation, Rousseau, A., Marquet, P., Kamar, N., Merville, P., Fruit, D., Bouchet, S., Lacroix, I., Coubret, A., Laroche, M. -L., Essig, M., Monchaud, C., Villeneuve, C., American Journal of Transplantation, 2015
  • Separative techniques for determination of buprenorphihe, Marquet, P, Kintz, P, Cirimele, V, Buprenorphine Therapy of Opiate Addiction, 2002
  • Buprenorphine poisoning in drug abusers on substitution therapy: 29 non-fatal and 20 fatal cases, Ludes, B, Jaeger, A, Petit, G, Pepin, G, Marquet, P, Ghysel, MH, Deveaux, M, Kintz, P, Kopferschmitt, J, Flesch, F, Tournoud, C, Tracqui, A, Presse Medicale, 1998
  • A Machine Learning Approach to Predict Interdose Vancomycin Exposure., Woillard JB, Wicha SG, Marquet P, Labriffe M, Sidorov E, Uster DW, Bououda M, Pharmaceutical research, 2022, 10.1007/s11095-022-03252-8
  • Concentration controled versus fixed dose of MMF in kidney transplant recipients: Preliminary results of a French multicenter randomized study., Marquet, P, Rerolle, JP, Szelag, JC, Thervet, E, Rostaing, L, Allard, C, Villemain, F, Caillard, S, Thierry, A, Westeel, PF, Etienne, I, Lavaud, S, Buchler, M, Le Meur, Y, American Journal of Transplantation, 2005
  • Application of machine learning to predict tacrolimus exposure in liver and kidney transplant patients given the MeltDose formulation., Woillard JB, Labriffe M, Monchaud C, van Hoek B, Rostaing L, Moes DJAR, Marquet P, Ponthier L, European journal of clinical pharmacology, 2022, 10.1007/s00228-022-03445-5
  • Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry, Marquet, Pierre, Lachatre, Gerard, Deporte, Didier, Duretz, Benedicte, Saint-Marcoux, Franck, Sauvage, Francois-Ludovic, Clinical Chemistry, 2006, 10.1373/clinchem.2006.067116
  • Implication of efflux transporters and CYP3A on the transepithelial flux of mTOR inhibitors across human intestinal Caco-2 cell monolayers and interaction with Cyclosporine A, Marquet, P., Picard, N., Boussera, B., Lamoureux, F., Fundamental & Clinical Pharmacology, 2009
  • A new insight in loratadine metabolism in human using LC-MS/MS detection and characterization, Marquet, Pierre, Bouehanas, Naceur A., Sauvage, Francois-Ludovic, Picard, Nicolas, Dridi, Dorra, Therapeutic Drug Monitoring, 2007
  • Untargeted Screening of Urinary Peptides Using Offline Nano-Liquid Chromatography: MALDI-TOF/TOF Mass Spectrometry., Marquet P, Passeron S, Sauvage FL, Methods in molecular biology (Clifton, N.J.), 2018, 10.1007/7651_2017_74
  • Influence of metabolic enzymes and efflux transporter polymorphisms on the plasma concentrations of MPA metabolites in renal transplant recipients., Rousseau, A, Szelag, JC, Le Meur, Y, Picard, N, Djebli, N, Marquet, P, American Journal of Transplantation, 2005
  • Structural patterns of the human ABCC4/MRP4 exporter in lipid bilayers rationalize clinically observed polymorphisms, , Pharmacological Research, 2018, 10.1016/j.phrs.2018.02.029
  • Darunavir unbound concentrations in plasma, not total concentration is the relevant concentration to predict darunavir efficacy in subject of different body mass index, Gandia, P., Delobel, P., Chatelut, E., Marquet, P., Debord, J., Seraissol, P., Toutain, P. L., Concordet, D., Woillard, J. B., Metsu, D., Fundamental & Clinical Pharmacology, 2018
  • Thyroid accumulation and adverse effects of imipramine and desipramine in rats after long-term administration, Raby, C, Lachatre, G, Buxeraud, J, Sauvage, MF, Lagorce, JF, Marquet, P, Rousseau, A, Pharmacology, 1998, 10.1159/000028248
  • Influence of cyclosporine dose on the main mycophenolate mofetil pharmacokinetic parameters, Stankevicius, Edgaras, Kadusevicius, Edmundas, Marquet, Pierre, Saint-Marcoux, Franck, Noreikaite, Aurelija, Acta Physiologica, 2016
  • Everolimus population pharmacokinetics and Bayesian estimators when associated to low-dose cyclosporine in kidney and heart transplantation, Marquet, Pierre, Rousseau, Annick, Debord, Jean, Saint-Marcoux, Franck, Therapeutic Drug Monitoring, 2007
  • Identificaion of a phase I metabolite of mycophenolic aced produced by CYP 450 3A4/5, Marquet, P, Le Meur, Y, Cresteil, T, Picard, N, Therapeutic Drug Monitoring, 2003
  • Adherence profiles in kidney transplant patients: Causes and consequences., , Patient education and counseling, 2019, 10.1016/j.pec.2019.08.002
  • Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients, Picard, Nicolas, Marquet, Pierre, Rostaing, Lionel, Rousseau, Annick, Kamar, Nassim, Woillard, Jean-Baptiste, Pharmacogenetics and Genomics, 2012, 10.1097/FPC.0b013e328357359d
  • Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Exposure in Heart Transplant Recipients: Comparison of Two Approaches, Saint-Marcoux, F., Marquet, P., Sinnasse-Raymond, G., Neely, M., Debord, J., Rousseau, A., Premaud, A., Woillard, J-B, Youdarene, R., Journal of Heart and Lung Transplantation, 2013
  • Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations in adult liver transplant patients, , British Journal of Clinical Pharmacology, 2019, 10.1111/bcp.13960
  • T-Cell Activation and Proliferation Measurements as Pharmacodynamic Biomarkers of Mycophenolic Acid Exposure., Kamar, Nassim, Rostaing, Lionel, Marquet, Pierre, Rousseau, Annick, Gandia, Peggy, Boehler, Torsten, Premaud, Aurelie, Canivet, Cindy, Johnson, Gyasi, American Journal of Transplantation, 2009
  • The Key Role of Warm and Cold Ischemia in Uterus Transplantation: A Review., , Journal of clinical medicine, 2019, 10.3390/jcm8060760
  • Decreased serum paraoxonase activity as a cardiovascular risk factor in chronic renal failure., LerouxRobert, C, Merle, L, Lachatre, G, Marquet, P, Charmes, JP, Debord, J, Dantoine, T, Journal of the American Society of Nephrology, 1997
  • ACOUSTIC PROPERTIES OF THE NORMAL CHEST, MENIER, R, MARQUET, P, ANTONINI, MT, DALMAY, F, European Respiratory Journal, 1995, 10.1183/09031936.95.08101761
  • Benefit of a 50% reduction of cyclosporine exposure in stable kidney transplant recipients treated with MMF without corticosteroids. the DICAM randomized study., Godin, M., Benichou, J., Hellot, M. F., Francois, A., Marquet, P., Westeel, P. F., Le Meur, Y., de Ligny, B. Hurault, Al Najjr, A., Thierry, A., Toupance, O., Etienne, I., American Journal of Transplantation, 2007
  • Development of a Bayesian Estimator for Dose Optimization of Mycophenolate Mofetil (MMF, Cellcept) in Heart Transplant Recipients on MMF-Tacrolimus: Preliminary Results of the PIGREC Trial., Monchaud, C., Sinasse-Raymond, G., Epailly, E., Redonnet, M., Guillemain, R., Rolle, F., Sebbag, L., Kamar, N., Marquet, P., American Journal of Transplantation, 2011
  • Quantitative proteomic analysis of cyclosporine-induced toxicity in a human kidney cell line and comparison with tacrolimus, Gastinel, L. N., Marquet, P., Sauvage, F. L., Essig, M., Mestre, E., Lamoureux, F., Journal of Proteomics, 2011, 10.1016/j.jprot.2011.09.005
  • Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in patients with autoimmune hepatitis., Prémaud A, Marquet P, Rousseau A, Woillard JB, Nanga TM, British journal of clinical pharmacology, 2022, 10.1111/bcp.15389
  • Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee, Wallemacq, Pierre, Wieland, Eberhard, Oellerich, Michael, Marquet, Pierre, Langman, Loralie J., Pawinski, Thomasz, Kunicki, Pawel K., Brunet, Merce, Holt, David W., Wang, Ping, Billaud, Elaine M., Christians, Uwe, Shipkova, Maria, Seger, Christoph, Therapeutic Drug Monitoring, 2016
  • A fully automated turbulent-flow liquid chromatography-tandem mass spectrometry technique for monitoring antidepressants in human serum, Marquet, P, Lachatre, G, Gaulier, JM, Sauvage, FL, Therapeutic Drug Monitoring, 2006, 10.1097/01.ftd.0000194026.04483.c3
  • Applications of liquid chromatography mass spectrometry in analytical toxicology: A review, Lachatre, G, Penicaut, B, Lotfi, H, Verneuil, B, Marquet, P, Hoja, H, Journal of Analytical Toxicology, 1997
  • Is there an optimal time to administer methotrexate in the treatment of rheumatoid arthritis?, Treves, R, Lachatre, G, Debord, J, Bonnet, C, Sabot, C, Marquet, P, Bertin, P, Carpentier, N, Journal of Rheumatology, 1998
  • Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients, Paintaud, G, Marquet, P, Lebranchu, Y, Le Meur, Y, Buchler, M, Bourgoin, H, Le Guellec, C, Clinical Pharmacokinetics, 2004, 10.2165/00003088-200443040-00004
  • Professor Folke Sjöqvist peacefully passed away on March 30, 2020., , European journal of clinical pharmacology, 2020, 10.1007/s00228-020-02911-2
  • A new strategy for faster urinary biomarkers identification by Nano-LC-MALDI-TOF/TOF mass spectrometry, Gastinel, L. N., Le Meur, Y., Rerolle, J. P., Marquet, P., Benkali, K., Bmc Genomics, 2008, 10.1186/1471-2164-9-541
  • Polymorphisms in donor P-gp influence renal function and graft loss in a long term cohort of renal transplant recipients, Marquet, P., Le Meur, Y., Drouet, M., Essig, M., Munteanu, E., Rousseau, A., Picard, N., Rerolle, J-P, Woillard, J-B, Fundamental & Clinical Pharmacology, 2010
  • TDM of mycophenolate mofetil co-administered with tacrolimus in kidney graft recipients; Experience using the free ISBA website providing Bayesian dose adjustment, Bentue-Ferrer, Daniele, Marquet, Pierre, LePogamp, Patrick, Rivalan, Joseph, Frouget, Thierry, Morin, Marie-Pascale, Saint-Marcolix, Franck, Tribut, Olivier, Therapeutic Drug Monitoring, 2007
  • Pharmacokinetic Modeling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving the Tacrolimus Once-Daily Formulation, Marquet, Pierre, Rousseau, Annick, Undre, Nasrullah, Debord, Jean, Saint-Marcoux, Franck, Therapeutic Drug Monitoring, 2010, 10.1097/FTD.0b013e3181cc70db
  • Buprenorphine withdrawal syndrome in a newborn, Lachatre, G, Merle, L, Lavignasse, P, Chevrel, J, Marquet, P, Clinical Pharmacology & Therapeutics, 1997, 10.1016/S0009-9236(97)90053-9
  • EVALUATING PATIENTS' PERCEPTION OF THEIR IMMUNOSUPPRESSIVE TREATMENT: A SIMPLE TOOL TO ENHANCE PATIENT ADHERENCE, Monchaud, C., Marquet, P., Loustaud-Ratti, V., Bert, K., Bonneau, A., Cleret, S., Dussoulier, I., Debette-Gratien, M., Grau, M., Villeneuve, C., Transplant International, 2017
  • Mass spectrometry platform in Limousin, Marquet, P., Gastinel, L. N., Bulletin Du Cancer, 2008
  • Mycophenolic Acid 12-Hour Area Under the Curve in De Novo Liver Transplant Patients Given Mycophenolate Mofetil at Fixed Versus Concentration-Controlled Doses, Rostaing, Lionel, Saint-Marcoux, Franck, Suc, Bertrand, Alric, Laurent, Peron, Jean Marie, Canivet, Cindy, Guitard, Joelle, Esposito, Laure, Lavayssi, Laurence, Muscari, Fabrice, Gandia, Peggy, Marquet, Pierre, Kamar, Nassim, Therapeutic Drug Monitoring, 2009
  • A Machine Learning Approach to Estimate the Glomerular Filtration Rate in Intensive Care Unit Patients Based on Plasma Iohexol Concentrations and Covariates., , Clinical pharmacokinetics, 2021, 10.1007/s40262-020-00927-6
  • CYP3A5 genotype influences differently the hepatic clearance of tacrolimus, sirolimus and everolimus, Marquet, Pierre, Sauvage, Francois-Ludovic, Djebli, Nassim, Picard, Nicolas, Therapeutic Drug Monitoring, 2007
  • [History of pharmacology-toxicology in Limoges]., au nom de la pharmacologie-toxicologie Limousine, Lachâtre G, Merle L, Laroche ML, Marquet P, Therapie, 2023, 10.1016/j.therap.2023.02.003
  • Analytical findings in a suicide involving sodium azide, Lachatre, G, Dumont, D, Debord, E, Dreyfuss, MF, Lotfi, H, Clement, S, Marquet, P, Journal of Analytical Toxicology, 1996
  • A single Bayesian estimator for iohexol clearance estimation in ICU, liver failure and renal transplant patients., Woillard JB, Marquet P, Barin-Le Guellec C, Ehrmann S, Carrier P, Loustaud-Ratti V, Åsberg A, Salmon Gandonnière C, Destere A, British journal of clinical pharmacology, 2022, 10.1111/bcp.15197
  • Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies, Lechat, Philippe, Piette, Jean Charles, Marquet, Pierre, Saint-Marcoux, Franck, Hulot, Jean-Sebastien, Debord, Jean, Amoura, Zahir, Zahr, Noeel, Clinical Pharmacokinetics, 2008
  • Is Intestinal Dysbiosis-Associated With Immunosuppressive Therapy a Key Factor in the Pathophysiology of Post-Transplant Diabetes Mellitus?, Lawson R, Marquet P, Picard N, Brossier C, Jardou M, Faucher Q, Frontiers in endocrinology, 2022, 10.3389/fendo.2022.898878
  • Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology., , Therapeutic drug monitoring, 2021, 10.1097/ftd.0000000000000871
  • Influence of MRP2 (C-24T) SNP on MPA-to-metabolites plasma ratios in renal transplant recipients, Marquet, P, Rousseau, A, Szelag, JC, Picard, N, Le Meur, Y, Djebli, N, Therapeutic Drug Monitoring, 2005
  • On the proportional abundance of species: Integrating population genetics and community ecology., Rebolledo R, Ganz A, Abades SR, Espinoza G, Marquet PA, Scientific reports, 2017, 10.1038/s41598-017-17070-1
  • Pharmacokinetic Tools for, and Clinical Findings in Favour of, the Therapeutic Drug Monitoring of Mycophenolate Mofetil in Children with Idiopathic Nephrotic Syndrome, Marquet, P., Berard, E., Broux, F., Harambat, J., Bouissou, F., Palcoux, J. B., Ranchin, B., Saint-Marcoux, F., Guigonis, V., Pediatric Nephrology, 2010
  • Pharmacokinetic study of mycophenolate mofetil and design of a Bayesian estimator based on a limited sampling strategy in patients with systemic lupus erythematosus, Lechat, P., Piette, J. C., Marquet, P., Saint-Marcoux, F., Hulot, J. S., Amoura, Z., Debord, J., Zahr, N., Fundamental & Clinical Pharmacology, 2007
  • The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation, Marquet, Pierre, Picard, Nicolas, Expert Opinion on Drug Metabolism & Toxicology, 2011, 10.1517/17425255.2011.570260
  • [Not Available]., Verstuyft, Celine, Tisseau, Anne, Pigeon, Martine, Perin-Dureau, Florent, Perche, Olivier, Morin-Surroca, Michele, Mourah, Samia, Hoog-Labouret, Natalie, Gueyffier, Francois, Goni, Sylvia, Froguel, Philippe, Divine, Marine, Diaz, Isabelle, Chatelut, Etienne, Cazeneuve, Beatrice, Auge, Pascale, Ameye, Veronique, les participants a la table ronde N°1 de Giens XXX :, Barlesi, Fabrice, Longeray, Pierre-Henry, Marquet, Pierre, Therapie, 2015, 10.2515/therapie/2014230
  • A Hybrid Algorithm Combining Population Pharmacokinetic and Machine Learning for Isavuconazole Exposure Prediction., Woillard JB, Drici MD, Labriffe M, Marquet P, Destere A, Pharmaceutical research, 2023, 10.1007/s11095-023-03507-y
  • Pharmacokinetic evaluation of MFF in combinations with tacrolimus and cyclosporine. Findings of C0 and AUC., , Medicine, 2020, 10.1097/md.0000000000019441
  • Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5, Marquet, Pierre, Sauvage, Francois-Ludovic, Djebli, Nassim, Picard, Nicolas, Drug Metabolism and Disposition, 2007, 10.1124/dmd.106.012161
  • First-Line Toxicological Screening with Fully Automated Extraction., , Journal of analytical toxicology, 2021, 10.1093/jat/bkaa075
  • In-source CID mass spectral libraries for the "general unknown" screening of drugs and toxicants, Lachatre, G, Lacassie, E, Venisse, N, Marquet, P, Analusis, 2000, 10.1051/analusis:2000280925
  • Tungsten determination in biological fluids, hair and nails by plasma emission spectrometry in a case of severe acute intoxication in man, Lachatre, G, Nedelec, G, Debord, J, Turcant, A, Lotfi, H, Francois, B, Marquet, P, Journal of Forensic Sciences, 1997
  • Quantitative proteomic analysis of CSA-induced toxicity in renal cells reveals the perturbation of multiple cellular pathways, Marquet, P., Gastinel, L., Essig, M., Lamoureux, F., Fundamental & Clinical Pharmacology, 2011
  • Sensitive and specific multiresidue methods for the determination of pesticides of various classes in clinical and forensic toxicology, Lachatre, G, Dreyfuss, MF, Gaulier, JM, Marquet, P, Lacassie, E, Forensic Science International, 2001, 10.1016/S0379-0738(01)00461-3
  • Multidrug resistance-associated protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients, Picard, Nicolas, Trouillas, Patrick, Marquet, Pierre, Woillard, Jean-Baptiste, Otyepka, Michal, Fabre, Gabin, Kaminski, Hannah, Rostaing, Lionel, Kamar, Nassim, Rerolle, Jean-Philippe, Essig, Marie, Saint-Marcoux, Franck, Ossman, Tahani, Billat, Pierre-Andre, Pharmacological Research, 2016, 10.1016/j.phrs.2016.07.012
  • Self-poisoning with 60 tablets of Apixaban, a pharmacokinetics case report., Woillard JB, Saint-Marcoux F, Marquet P, Couderc S, Picard N, Monchaud C, El Balkhi S, Dulaurent S, Franck B, British journal of clinical pharmacology, 2018, 10.1111/bcp.13790
  • Intravenous induction of acute arsenic poisoning, Leonetti, G, Panteix, G, Marquet, P, Salerio, G, Pelissier-Alicot, AL, Presse Medicale, 2003
  • Genetic polymorphisms of the calcineurin pathway and their implication in renal transplant patient outcomes, Picard, N., Marquet, P., Petersen, B., Le Meur, Y., Bouchet, S., Gandia, P., Merville, P., Kamar, N., Essig, M., Monchaud, C., Stojanova, J., Villeneuve, C., Woillard, J., Koikta, M., Pouche, L., Fundamental & Clinical Pharmacology, 2015
  • Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART, COPHAR2 ANRS 111 Study Grp, Mentre, France, Duval, Xavier, Salmon-Ceron, Dominique, Rey, Elisabeth, Auleley, Solange, Tran, Agnes, Panhard, Xaviere, Treluyer, Jean-Marc, Bertrand, Julie, European Journal of Clinical Pharmacology, 2009, 10.1007/s00228-009-0660-5
  • CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients, Marquet, Pierre, Rostaing, Lionel, Kamar, Nassim, Rouguieg-Malki, Koukeb, Picard, Nicolas, Transplantation, 2011, 10.1097/TP.0b013e31820ae4ac
  • Uterine transplantation: Is there a real demand?, Aubard, Y., Marquet, P., Pichon, N., Essig, M., Piver, P., Therme, J. -F., Garnault, D., Gauthier, T., Gynecologie Obstetrique & Fertilite, 2015, 10.1016/j.gyobfe.2014.12.005
  • Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8*2 variant allele, Le Meur, Yann, Marquet, Pierre, Essig, Marie, Munteanu, Eliza, Drouet, Mireille, Rousseau, Annick, Picard, Nicolas, Rerolle, Jean-Philippe, Woillard, Jean-Baptiste, British Journal of Clinical Pharmacology, 2010, 10.1111/j.1365-2125.2010.03625.x
  • BREATHS SOUNDS, MARQUET, P, Revue Des Maladies Respiratoires, 1995
  • Advagraf (R) Pharmacokinetics Analysis in Stable Renal Transplant Patients., Rostaing, Lionel, Rousseau, Annick, Marquet, Pierre, Premaud, Aurelie, Kamar, Nassim, Benkali, Khaled, American Journal of Transplantation, 2009
  • Screening of pesticides in blood with liquid chromatography-linear ion trap mass spectrometry, Lachatre, Gerard, Gaulier, Jean-Michel, Marquet, Pierre, Moesch, Christian, Dulaurent, Sylvain, Analytical and Bioanalytical Chemistry, 2010, 10.1007/s00216-009-3443-z
  • HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF NAVELBINE IN HUMAN PLASMA AND URINE, ROCCA, JL, VALLETTE, JP, BONNAUD, F, MARQUET, P, LACHATRE, G, NICOT, G, Journal of Chromatography-Biomedical Applications, 1990, 10.1016/S0378-4347(00)82384-1
  • High-dose buprenorphine fog treatment of opioid dependence, Marquet, P, Kintz, P, Strain, EC, Buprenorphine Therapy of Opiate Addiction, 2002
  • Thoroughly Validated Bayesian Estimator and Limited Sampling Strategy for Dose Individualization of Ganciclovir and Valganciclovir in Pediatric Transplant Recipients., , Clinical pharmacokinetics, 2021, 10.1007/s40262-021-01034-w
  • Population pharmacokinetic model and Bayesian estimator of a generic formulation of cyclosporine in Tunisian renal transplant patients, Saint-Marcoux, F., Marquet, P., Lakhal, M., Klouz, A., Jebari, H., Woillard, J. B., Gaies, E., Fundamental & Clinical Pharmacology, 2012
  • Translational Research: Precision Medicine, Personalized Medicine, Targeted Therapies: Marketing or Science?, Verstuyft, Celine, Tisseau, Anne, Pigeon, Martine, Perin-Dureau, Florent, Perche, Olivier, Morin-Surroca, Michele, Mourah, Samia, Hoog-Labouret, Natalie, Gueyffier, Francois, Goni, Sylvia, Froguel, Philippe, Divine, Marine, Diaz, Isabelle, Chatelue, Etienne, Cazeneuve, Beatrice, Auge, Pascale, Ameye, Veronique, Barlesi, Fabrice, Longeray, Pierre-Henry, Marquet, Pierre, Therapie, 2015, 10.2515/therapie/2014231
  • Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters Cross-sectional study, Stankevicius, E., Kadusevicius, E., Marquet, P., Saint-Marcoux, F., Noreikaite, A., Medicine, 2017, 10.1097/md.0000000000006469
  • Population Pharmacokinetic Modeling Approach to compare different vancomycin dose rates in premature neonates according to weight and serum creatinine values, Saint-Marcoux, F., Marquet, P., Guigonis, V., Neely, M., Lebreton, V., Casagrande, K., Nolain, P., Woillard, J. B., Fundamental & Clinical Pharmacology, 2015
  • Significant Influence of Hematocrit on Tacrolimus Apparent Clearance in Renal Transplant Patients., Rousseau, Annick, Marquet, Pierre, Le Meur, Yannick, Turcant, Alain, Villemain, Florence, Olivier, Toupance, Hoizey, Guillaume, Rerolle, Jean-Philippe, Premaud, Aurelie, Benkali, Khaled, American Journal of Transplantation, 2009
  • Decrease of serum paraoxonase activity in chronic renal failure, Leroux-Robert, C, Lachatre, G, Marquet, P, Merle, L, Charmes, JP, Debord, J, Dantoine, TF, Journal of the American Society of Nephrology, 1998
  • Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia, , Drugs in R&D, 2019, 10.1007/s40268-019-0268-x
  • Urinary Protein Biomarker Panel for the Diagnosis of Antibody-Mediated Rejection in Kidney Transplant Recipients., , Kidney international reports, 2020, 10.1016/j.ekir.2020.06.018
  • Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure, Cattaneo, Dario, van Gelder, Teun, Kuypers, Dirk R., Marquet, Pierre, Miura, Masatomo, Vinks, Alexander A., Brunet, Merce, Staatz, Christine E., Saint-Marcoux, Franck, Tett, Susan E., Transplantation Reviews, 2011, 10.1016/j.trre.2010.06.001
  • Development of Bayesian estimators for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome, Marquet, P., Berard, E., Broux, F., Harambat, J., Bouissou, F., Palcoux, J., Guigonis, V., Ranchin, B., Saint-Marcoux, F., Fundamental & Clinical Pharmacology, 2009
  • Simultaneous determination of amphetamine and its analogs in human whole blood by gas chromatography mass spectrometry, Lachatre, G, Faubert, H, Battu, C, Lacassie, E, Marquet, P, Journal of Chromatography B, 1997, 10.1016/S0378-4347(97)00318-6
  • The EPIGREN study: validation of collection tools in a French cohort of renal transplant patients, Laroche, M. L., Marquet, P., Rostaing, L., Merville, P., Essig, M., Villeneuve, C., Rousseau, A., Fruit, D., Fundamental & Clinical Pharmacology, 2013
  • Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation, Marquet, P., Touchard, G., Rousseau, A., Rerolle, J.-P., Szelag, J. C., Thervet, E., Rostaing, L., de Ligny, B. H., Westeel, P.-F., Etienne, I., Lavaud, S., Villemain, F., Caillard, S., Thierry, A., Buechler, M., Le Meur, Y., American Journal of Transplantation, 2007, 10.1111/j.1600-6143.2007.01983.x
  • Cost-Effectiveness Analysis of Individualized Mycophenolate Mofetil Dosing in Kidney Transplant Patients in the APOMYGRE Trial, Marquet, Pierre, Le Meur, Yannick, Vergnenegre, Alain, Villeneuve, Claire, Buchler, Mathias, Jacqz-Aigrain, Evelyne, Saivin, Sylvie, Debruyne, Daniele, Hary, Lionel, Compagnon, Patricia, Hoizey, Guillaume, Turcant, Alain, Loichot-Roselmac, Cecile, Venisse, Nicolas, Laroche, Marie-Laure, Rousseau, Annick, Transplantation, 2010, 10.1097/TP.0b013e3181d75952
  • A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen, , American Journal of Transplantation, 2018, 10.1111/ajt.14894
  • Optimizing ribavirin dosage: A new challenge to improve treatment efficacy in genotype 1 hepatitis C patients, French Ribavirin Grp OPTIRIB, Trepo, C., Babany, G., Maynard, M., Gagnieu, M. -C., Marquet, P., Stanke-Labesque, F., Loustaud-Ratti, V., Gastroenterologie Clinique Et Biologique, 2009, 10.1016/j.gcb.2009.04.009
  • Exploring different DNA extraction and genotyping techniques in medium-scale pharmacogenetic research, Picard, N., Marquet, P., Abraham, J., Koitka, M., Fundamental & Clinical Pharmacology, 2011
  • Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies., , Journal of the American Society of Nephrology : JASN, 2020, 10.1681/asn.2020030306
  • NEUROTOXICITY OF TACROLIMUS IN RENAL TRANSPLANT PATIENTS: RELATIONSHIP BETWEEN TREMOR AND EXPOSURE TO TACROLIMUS, Marquet, Pierre, Monchaud, Caroline, Buchler, Matthias, Etienne, Isabelle, Westeel, Pierre-Francois, Rostaing, Lionel, Kamar, Nassim, Merville, Pierre, Lacroix, Isabelle, Bouchet, Stephane, Coubret, Anne, Laroche, Marie-Laure, Essig, Marie, Berthier, Joseph, Transplant International, 2015
  • Toxicity of tungsten - Reply, Lachatre, G, Vignon, P, Francois, B, Marquet, P, Lancet, 1997, 10.1016/S0140-6736(05)62195-2
  • In vitro and in vivo study of the antithyroid side effects of trimeprazine, Lachatre, G, Raby, C, Dumeirain, F, Marquet, P, Rousseau, A, Sauvage, MF, Toxicology and Applied Pharmacology, 1999, 10.1006/taap.1999.8699
  • Serotonin syndrome due to an overdose of moclobemide and clomipramine - A potentially life-threatening association, Gastinne, H, Lachatre, G, Roustan, J, Desachy, A, Marquet, P, Francois, B, Intensive Care Medicine, 1997, 10.1007/s001340050303
  • Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial., Koch A, Fischereder M, Arns W, Matz M, Budde K, Marquet P, Anglicheau D, Van Loon E, Naesens M, Metzger J, Khalifa AA, Braesen JH, Karch A, Gwinner W, Transplantation direct, 2022, 10.1097/txd.0000000000001316
  • Strychnine poisoning in rural areas, Gay, R, Lachatre, G, Billy, V, Marquet, P, Cailloce, D, Francois, B, Presse Medicale, 1996
  • Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients, Rousseau, Annick, Marquet, Pierre, Le Meur, Yannick, Villemain, Florence, Turcant, Alain, Hoizey, Guillaume, Toupance, Olivier, Rerolle, Jean-Philippe, Picard, Nicolas, Premaud, Aurelie, Benkali, Khaled, Clinical Pharmacokinetics, 2009
  • Prognostic value of ribavirin AUC0-12 h after the first dose in genotype 1 chronic hepatitis C patients given ribavirin and peginterferon alpha-2a (40 kDa), Marquet, P., Vidal, E., Cales, P., Lefevre, A., Fouchard-Hubert, I., Sauvage, F. L., Alain, S., Loustaud-Ratti, V., Rousseau, A., Fundamental & Clinical Pharmacology, 2007
  • 2019 American Transplant Congress Abstracts., , American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2019, 10.1111/ajt.15405
  • Identification and quantitation of six non-depolarizing neuromuscular blocking agents by LC-MS in biological fluids, Lachatre, U, Gaulier, JM, Dupuy, JL, Marquet, P, Quintela, O, Sayer, H, Journal of Analytical Toxicology, 2004
  • Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs, Marquet, P, Rousseau, A, Fundamental & Clinical Pharmacology, 2002, 10.1046/j.1472-8206.2002.00086.x
  • New Tools for Mycophenolate Mofetil (MMF) Dose Optimization in Heart and/or Lung Transplant Recipients during the First Year Post-Transplant: Preliminary Results of the PIGREC and STIMMUGREP Trials, Marquet, Pierre, Stern, Marc, Sebbag, Laurent, Redonnet, Michel, Kessler, Romain, Dromer, Claire, Rolle, Florence, Saint-Marcoux, Franck, American Journal of Transplantation, 2010
  • Mycophenolate Mofetil Dose Adjustment in Pediatric Kidney Transplant Recipients., Marquet P, Debord J, Saint-Marcoux F, Monchaud C, Woillard JB, Micallef L, Labriffe M, Therapeutic drug monitoring, 2023, 10.1097/ftd.0000000000001087
  • Population pharmacokinetic modeling of oral cyclosporin using NONMEM - Comparison of absorption pharmacokinetic models and design of a Bayesion estimator, Marquet, P, Buchler, M, Paintaud, G, Saint-Marcoux, F, Le Meur, Y, Leger, F, Rousseau, A, Therapeutic Drug Monitoring, 2004, 10.1097/00007691-200402000-00006
  • In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways, Marquet, P, Djebli, N, Cresteil, T, Picard, N, Drug Metabolism and Disposition, 2005, 10.1124/dmd.105.003681
  • Bridging the Worlds of Pharmacometrics and Machine Learning, Mihaela van der Schaar, Pierre Marquet, Richard W. Peck, Jean-Baptiste Woillard, Kamilė Stankevičiūtė, Clinical Pharmacokinetics, 2023, 10.1007/s40262-023-01310-x
  • Large Scale Analysis of Routine Dose Adjustments of Mycophenolate Mofetil Based on Global Exposure in Renal Transplant Patients, Marquet, Pierre, Rousseau, Annick, Debord, Jean, Premaud, Aurelie, Vandierdonck, Soizic, Saint-Marcoux, Franck, Therapeutic Drug Monitoring, 2011, 10.1097/FTD.0b013e31821633a6
  • Mechanisms underlying postmortem redistribution of drugs: A review, Marquet, P, Champsaur, P, Gaulier, JM, Pelissier-Alicot, AL, Journal of Analytical Toxicology, 2003
  • An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine, Marquet, P, Laurentie, M, Manceau, J, Ragot, S, Gicquel, M, Rousseau, A, Premaud, A, Toxicology and Applied Pharmacology, 2002, 10.1006/taap.2002.9467
  • Biomarker research in urinary peptidoma for early diagnosis of renal graft dysfunction, Gastinel, L. N., Essig, M., Rerolle, J. P., Le Meur, Y., Marquet, P., Benkali, K., Bulletin Du Cancer, 2008
  • Fatal intoxications with chloral hydrate, Lachatre, G, Marquet, P, Haglund, P, Courtiade, B, Lacassie, E, Merle, G, Gaulier, JM, Journal of Forensic Sciences, 2001
  • Development of a Bayesian estimator based on limited sampling strategies for Advagraf (R) and Prograf (R) in de novo adult liver transplant patients, Woillard, J. B., Marquet, P., Debord, J., Riff, C., Fundamental & Clinical Pharmacology, 2017
  • Immunosuppressant dosing accuracy. Residual drug concentration versus estimation of the area under the curve, Stankevicius, E., Kadusevicius, E., Woillard, J. B., Marquet, P., Saint-Marcoux, F., Noreikaite, A., Acta Physiologica, 2017
  • Tools for routine dose adjustment of mycophenolate mofetil based on MPA AUC Bayesian estimation: Experience with a new enzymatic assay, Marquet, Pierre, Tiberi, Marco, Domke, Ingrid, Debord, Jean, Sauvage, Francois-Ludovic, Saint-Marcoux, Franck, Therapeutic Drug Monitoring, 2007
  • Mapping cyclosporine-induced changes in protein secretion by renal cells using stable isotope labeling with amino acids in cell culture (SILAC), Essig, M., Marquet, P., Mestre, E., Gastinel, L. N., Lamoureux, F., Journal of Proteomics, 2012, 10.1016/j.jprot.2012.04.024
  • Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy, , Therapeutic Drug Monitoring, 2019, 10.1097/ftd.0000000000000640
  • CYCLOSPORINE A, BUT NOT TACROLIMUS, INHIBITS THE SERUM RESPONSIVE PATHWAY OF PROXIMAL TUBULAR CELLS THROUGH COFILIN INHIBITION AND REORGANIZATION OF F-ACTIN BRANCHED MESHWORK, Essig, M., Marquet, P., Pinault, E., Sauvage, F. L., Gonzalez, J., Burat, B., Transplant International, 2017
  • Biological pathways and comparison with biopsy signals and cellular origin of peripheral blood transcriptomic profiles during kidney allograft pathology., Naesens M, Koshy P, Cortés Calabuig Á, Tinel C, Callemeyn J, Giral M, Danger R, Brouard S, Van Craenenbroeck AH, de Loor H, Lamarthée B, Van Loon E, Kidney international, 2022, 10.1016/j.kint.2022.03.026
  • Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil, Marquet, Pierre, Van Gelder, Teun, Woillard, Jean-Baptiste, Rousseau, Annick, Le Meur, Yannick, Picard, Nicolas, Van Schaik, Ron H. N., Gensburger, Olivier, Pharmacogenetics and Genomics, 2010, 10.1097/FPC.0b013e32833d8cf5
  • Stability of Ribavirin Concentrations Depending on the Type of Blood Collection Tube and Preanalytical Conditions, Lachatre, Gerard, Rousseau, Annick, Babany, Gerard, Loustaud-Ratti, Veronique, Sauvage, Francois-Ludovic, Marquet, Pierre, Therapeutic Drug Monitoring, 2010, 10.1097/FTD.0b013e3181d3f686
  • Rheumatoid Factor Interference in a Tacrolimus Immunoassay, Fortuny Marques, Regina, Riesco Prieto, Maria, Barcelo Bennasar, Antonia, Castanyer Puig, Bartomeu, Maria Ferrer, Joana, Marquet, Pierre, Barcelo Martin, Bernardi, Therapeutic Drug Monitoring, 2009
  • Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation, MPA, van Gelder, Teun, Chapman, Jeremy, Holt, David W., Toenshoff, Burkhard, Cattaneo, Dario, Tett, Susan E., Tredger, Michael J., Cantarovich, Marcelo, Le Meur, Yannick, Kuypers, Dirk R. J., Clinical Journal of the American Society of Nephrology, 2010, 10.2215/CJN.07111009
  • Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions, Estenne, M, Marquet, P, Rousseau, A, Saint-Marcoux, F, Thiry, P, Knoop, C, American Journal of Transplantation, 2005, 10.1111/j.1600-6143.2005.00870.x
  • Multicenter evaluation of the roche total mycophenolic acid assay on COBAS INTEGRA (R) systems, Shaw, L., Oellerich, M., Engelmayer, J., Schmitz, G., Domke, I., Coffing, M. J., Liebisch, G., Marquet, P., Korecka, M., Figurski, M., Luthe, H., Therapeutic Drug Monitoring, 2007
  • PHARMACOKINETICS OF VINORELBINE IN MAN, NICOT, G, BONNAUD, F, DEBORD, J, EICHLER, B, LACHATRE, G, MARQUET, P, European Journal of Clinical Pharmacology, 1992, 10.1007/BF00314866
  • Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation, Oellerich, Michael, Wallemacq, Pierre, Pawinski, Tomasz, Noceti, Ofelia, Hesselink, Dennis A., Marquet, Pierre, Millan Lopez, Olga, Picard, Nicolas, Bergan, Stein, Barten, Markus J., Lopez-Hoyos, Marcos, Christians, Uwe, Haufroid, Vincent, Budde, Klemens, Sommerer, Claudia, Wieland, Eberhard, van Gelder, Teun, Shipkova, Maria, Brunet, Merce, Therapeutic Drug Monitoring, 2016
  • Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection., , American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2020, 10.1111/ajt.15959
  • Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships, Kamar, Nassim, Marquet, Pierre, Rostaing, Lionel, Peron, Jean Marie, Muscari, Fabrice, Gandia, Peggy, Canivet, Cindy, Johnson, Gyasi, Rousseau, Annick, Premaud, Aurelie, Pharmacological Research, 2011, 10.1016/j.phrs.2011.01.005
  • General unknown screening procedure for the characterization of human drug metabolites in forensic toxicology: Applications and constraints, Marquet, Pierre, Lachatre, Gerard, Gaulier, Jean-Michel, Saint-Marcoux, Franck, Picard, Nicolas, Sauvage, Francois-Ludovic, Journal of Separation Science, 2009, 10.1002/jssc.200900092
  • Evidence for Hematocrit Influence on Tacrolimus Apparent Clearance and Application for TDM in Renal Transplant Recipients, Marquet, P., Rousseau, A., Le Meur, Y., Turcant, A., Villemain, F., Toupance, O., Hoizey, G., Rerolle, J. P., Picard, N., Premaud, A., Benkali, K., Therapeutic Drug Monitoring, 2009
  • A specific analytical method for the analysis of 24 antidepressants using gas chromatography-mass spectrometry (GC/MS), Lachatre, G, Marquet, P, Gaulier, JM, Ragot, S, Lacassie, E, Acta Clinica Belgica, 1999
  • Changes in the metabolic composition of storage solution with prolonged cold ischemia of the uterus, , Journal of Assisted Reproduction and Genetics, 2019, 10.1007/s10815-019-01477-y
  • Modeling of the Exposure to Tacrolimus in Kidney Transplantation, Aouam, K., Saint-marcoux, F., Marquet, P., Boughattas, N., Ben Fadhel, N., Chadly, Z., Chaabane, A., Debord, J., Woillard, J. B., Ben Fredj, N., Therapeutic Drug Monitoring, 2013
  • A Hybrid Model Associating Population Pharmacokinetics with Machine Learning: A Case Study with Iohexol Clearance Estimation., Woillard JB, Premaud A, Guellec CB, Ehrmann S, Carrier P, Loustaud-Ratti V, Åsberg A, Gandonnière CS, Marquet P, Destere A, Clinical pharmacokinetics, 2022, 10.1007/s40262-022-01138-x
  • A Population Pharmacokinetic Modeling Approach to Determine the Efficacy of Intravenous Amikacin in Children with Cystic Fibrosis., , Therapeutic drug monitoring, 2020, 10.1097/ftd.0000000000000855
  • Pharmacological & pharmacogenetic factors in post-transplant lymphoproliferative disease: feasibility of matching in a case-control study, Marquet, P., Essig, M., Rerolle, J. P., Roussel, H., Rousseau, A., Caillard, S., Stojanova, J., Therapeutic Drug Monitoring, 2011
  • Pretransplantation calcineurin activity: towards individualized therapy?, Marquet, Pierre, Liver International, 2009, 10.1111/j.1478-3231.2009.02146.x
  • Mycophenolate pharmacokinetics in cystic fibrosis and non-cystic fibrosis lung transplant recipients: preliminary results of the STIMMUGREP trial, Marquet, P., Rousseau, A., Romain, G., Dromer, C., Marc, E., Stern, M., Reynaud-Gaubert, M., Kessler, R., Pison, C., Monchaud, C., Fundamental & Clinical Pharmacology, 2009
  • Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients., , British journal of clinical pharmacology, 2020, 10.1111/bcp.14719
  • Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus, Marquet, Pierre, Sauvage, Francois-Ludovic, Boussera, Belkacem, Picard, Nicolas, Lamoureux, Fabien, Fundamental & Clinical Pharmacology, 2012, 10.1111/j.1472-8206.2011.00957.x
  • Limited Sampling Models and Bayesian Estimation for Mycophenolic Acid Area under the Curve Prediction in Stable Renal Transplant Patients Co-Medicated with Ciclosporin or Sirolimus, Verbeeck, Roger K., Wallemacq, Pierre, Marquet, Pierre, Cumps, Jean, Senessael, Jean-Jacques, Bosmans, Jean-Louis, Rousseau, Annick, Musuamba, Flora T., Clinical Pharmacokinetics, 2009
  • Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients, Lemay, Djamila, Chaouche-Teyara, Kamel, Marquet, Pierre, Dehennault, Maud, Foulard, Michel, Cailliez, Mathilde, Tsimaratos, Michel, Lapeyraque, Anne-Laure, Loirat, Chantal, Charbit, Marina, Niaudet, Patrick, Pediatric Nephrology, 2009, 10.1007/s00467-008-1031-7
  • Sensitive determination of vinorelbine and its metabolites in human serum using liquid chromatography-electrospray mass spectrometry, Marquet, P, Tubiana-Mathieu, N, Dupuy, JL, Genet, D, Rousseau, A, Ragot, S, Sauvage, FL, Journal of Chromatography B, 2001, 10.1016/S0378-4347(00)00408-4
  • Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part I, Marquet, Pierre, Monchaud, Caroline, Clinical Pharmacokinetics, 2009
  • A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits, Godin, Michel, Hellot, Marie-France, Francois, Arnaud, Marquet, Pierre, Westeel, Pierre-Francois, Le Meur, Yannick, de Ligny, Bruno Hurault, Al Najjar, Azmi, Thierry, Antoine, Benichou, Jacques, Toupance, Olivier, Etienne, Isabelle, Nephrology Dialysis Transplantation, 2010, 10.1093/ndt/gfq135
  • Adaptive control methods for the dose individualisation of anticancer agents, Lachatre, G, Sabot, C, Debord, J, Marquet, P, Rousseau, A, Clinical Pharmacokinetics, 2000, 10.2165/00003088-200038040-00003
  • Ribavirin in chronic hepatitis C: past and future, Alain, Sophie, Denis, Francois, Marquet, Pierre, Rousseau, Annick, Loustaud-Ratti, Veronique, Expert Review of Anti-Infective Therapy, 2009, 10.1586/eri.09.5
  • In-vivo and in-vitro study of cyclosporin and Sirolimus pharmacokinetic interactions with mycophenolate mofetil, Marquet, P, Rousseau, A, Szelag, JC, Toupance, O, Le Meur, Y, Hoizey, G, Picard, N, Therapeutic Drug Monitoring, 2005
  • Methods for the determination of seven selective serotonin reuptake inhibitors and three active metabolites in human serum using high-performance liquid chromatography and gas chromatography, Lachatre, G, Rabatel, JF, Marquet, P, Gaulier, JM, Lacassie, E, Journal of Chromatography B, 2000, 10.1016/S0378-4347(00)00159-6
  • Longitudinal Exposure to Tacrolimus and New-Onset Diabetes Mellitus in Renal Transplant Patients., Woillard JB, Marquet P, Monchaud C, Premaud A, Destere A, Therapeutic drug monitoring, 2023, 10.1097/ftd.0000000000001035
  • Clinical application of population pharmacokinetic methods developed for immunosuppressive drugs, Marquet, P, Therapeutic Drug Monitoring, 2005, 10.1097/01.ftd.0000179848.65266.aa
  • Substrate binding and lipid-mediated allostery in the human organic anion transporter 1 at the atomic-scale, Florent Di Meo, Pierre Marquet, Chantal Barin-Le Guellec, Nicolas Védrenne, Hélène Arnion, Quentin Faucher, Ágota Tóth, Angelika Janaszkiewicz, 2022, 10.1101/2022.07.14.500056
  • Tacrolimus population pharmacokinetics and bayesian estimation in tunisian renal transplant recipients, Marquet, P., Saint-Marcoux, F., Lakhal, M., Klouz, A., Jebari, H., Woillard, J. B., Gaies, E., Fundamental & Clinical Pharmacology, 2012
  • Ischemia/reperfusion-associated tubular cells injury in renal transplantation: Can metabolomics inform about mechanisms and help identify new therapeutic targets?, Hauet, T., Marquet, P., Bon, D., Largeau, B., Barin-Le Guellec, C., Pharmacological Research, 2018, 10.1016/j.phrs.2017.12.032
  • How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation, Marquet, Pierre, Essig, Marie, Bocquentin, Frederique, Friedl, Jennifer, Monchaud, Caroline, Woillard, Jean-Baptiste, Saint-Marcoux, Franck, Pharmacological Research, 2015, 10.1016/j.phrs.2015.08.020
  • Establishing Biomarkers in Transplant Medicine: A Critical Review of Current Approaches., , Transplantation, 2016, 10.1097/tp.0000000000001321
  • A screening procedure for the determination of 13 oral anticoagulants and rodenticides, Lachatre, C, Merle, L, Debord, J, Marquet, P, Dreyfuss, MF, Lotfi, H, Journal of Analytical Toxicology, 1996
  • How to predict clinical outcome in kidney transplantation? A dynamic, early marker of long-term graft survival, Rousseau, A., Marquet, P., Munteanu, E., Woillard, J. B., Essig, M., Abdi, Daher Z., Therapeutic Drug Monitoring, 2011
  • Analytical evaluation of the Abbott ARCHITECT cyclosporine assay in comparison to LC/MS/MS and Dade Dimension Xpand, Wonigeit, K., Marquet, P., Aimo, G., Schmid, R. W., Schmidt, E., Berg, K., Young, J., Ait-Youcef, H., Wallemacq, P., Maine, G. T., Clinical Biochemistry, 2008, 10.1016/j.clinbiochem.2008.08.032
  • Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis, Marquet, P, Thiry, P, Estenne, M, Vervier, I, Debord, J, Monchaud, C, Rousseau, A, Therapeutic Drug Monitoring, 2003, 10.1097/00007691-200302000-00004
  • Prevalence of drugs of abuse in urine of drivers involved in road accidents in France: A collaborative study, Seguela, JP, Vest, P, Renaudeau, C, Pelissier, AL, Mathe, D, Lhermitte, M, Guery, B, Garnier, M, Facy, F, Bremond, J, Kerguelen, S, Delpla, PA, Marquet, P, Journal of Forensic Sciences, 1998
  • Effects of dexamethasone on adrenal steroid plasma levels in healthy subjects at work, Habrioux, G, Galen, FX, Chassain, AP, Marquet, P, Egloff, M, Lafarge, P, Science & Sports, 1997, 10.1016/S0765-1597(97)80691-0
  • Multisite Analytical Evaluation of the Abbott ARCHITECT Cyclosporine Assay, Schmid, Rainer W., Wermuth, Bendicht, Kretschmer, Robert, Wonigeit, Kurt, Young, Julianna, Mengozzi, Giulio, Aimo, Giuseppe, Marquet, Pierre, Rosiere, Thomas, Berg, Keith, Maine, Gregory T., Wallemacq, Pierre, Therapeutic Drug Monitoring, 2010, 10.1097/FTD.0b013e3181d46386
  • A Chinese cream (Fu Suo) for psoriasis, Marquet, P, Bonnetblanc, JM, Dermatology, 1996
  • VALIDATION OF A FRENCH SELF-ADMINISTRATED QUESTIONNAIRE ABOUT QUALITY OF LIFE IN RENAL TRANSPLANT RECIPIENTS TRANSPLANTED FOR LESS THAN 12 MONTHS, Marquet, Pierre, Jouve, Elisabeth, Rousseau, Annick, Gentile, Stephanie, Laroche, Marie-Laure, Beauger, Davy, Fruit, Dorothee, Transplant International, 2012
  • Uterine Factor Infertility, a Systematic Review., Gauthier T, Dion L, Lavoué V, Aubard Y, Piver P, Marquet P, Margueritte F, Sallée C, Journal of clinical medicine, 2022, 10.3390/jcm11164907
  • Bayesian estimation of mycophenolic acid in renal transplant patients, Paintaud, G., Autret-Leca, E., Lebranchu, Y., Debord, J., Buchler, M., Marquet, P., Bourgoin, H., Le Guellec, C., Fundamental & Clinical Pharmacology, 2001
  • Population Pharmacokinetics And Bayesian Estimation of Mycophenolate Mofetil In Patients With Autoimmune Hepatitis, Prémaud A, Marquet P, Rousseau A, Woillard J, Nanga T, 2021, 10.22541/au.163577198.80163436/v1
  • Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome, Marquet, P., Compagnon, P., Broux, F., Bouchet, S., Harambat, J., Libert, F., Bessenay, L., Parant, F., Ranchin, B., Gandia, P., Decramer, S., Guigonis, V., Saint-Marcoux, F., Pharmacological Research, 2011, 10.1016/j.phrs.2011.01.009
  • Substrate binding and lipid-mediated allostery in the human organic anion transporter 1 at the atomic-scale., Di Meo F, Marquet P, Barin-Le Guellec C, Védrenne N, Arnion H, Faucher Q, Tóth Á, Janaszkiewicz A, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, 10.1016/j.biopha.2023.114342
  • Tools for routine dose adjustment of mycophenolate mofetil based on MPA AUC bayesian estimation: The experience with a new enzymatic assay, Marquet, Pierre, Tiberi, Marco, Domke, Ingrid, Debord, Jean, Sauvage, Francois-Ludovic, Saint-Marcoux, Franck, Transplant International, 2007
  • Sirolimus oral clearance is significantly higher in CYP3A5*1 vs CYP3A5*3 de novo renal transplant recipients with no associated calcineurin inhibitor., Le Meur, Y, Rousseau, A, Hoizey, G, Toupance, O, Djebli, N, Marquet, P, American Journal of Transplantation, 2005
  • Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction, Thervet, E., Legendre, C., Beaune, P., Meria, P., Cassinat, B., Marquet, P., Rabant, M., Pallet, N., Anglicheau, D., Kidney International, 2006, 10.1038/sj.ki.5001649
  • Pesticide contamination of workers in vineyards in France, Marquet, P, Dulaurent, S, Rougetet, L, Jean, S, Lebailly, P, Baldi, I, Journal of Exposure Science and Environmental Epidemiology, 2006, 10.1038/sj.jea.7500443
  • Effects of Calcineurin Inhibitors and Implication of Efflux Transporters and CYP3A on the Intestinal Flux of mTOR Inhibitors, Marquet, P., Sauvage, F. L., Picard, N., Lamoureux, F., Therapeutic Drug Monitoring, 2009
  • SILAC quantitative proteomic analysis of calcineurin inhibitors-induced toxicity in a human kidney cell line reveals different toxicity profiles between cyclosporine and tacrolimus, Gastinel, L. N., Essig, M., Sauvage, F. L., Marquet, P., Mestre, E., Lamoureux, F., Therapeutic Drug Monitoring, 2011
  • A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation, Picard, Nicolas, Marquet, Pierre, Petersen, Britt-Sabina, Bouchet, Stephane, Gandia, Peggy, Merville, Pierre, Rostaing, Lionel, Kamar, Nassim, Rerolle, Jean-Phillippe, Le Meur, Yannick, Abraham, Julie, Essig, Marie, Villeneuve, Claire, Monchaud, Caroline, Woillard, Jean -Baptiste, Stojanova, Jana, Koitka, Matthias, Pouche, Lucie, Pharmacogenomics, 2016, 10.2217/pgs.15.181
  • Progress of liquid chromatography-mass spectrometry in clinical and forensic toxicology, Marquet, P, Therapeutic Drug Monitoring, 2002, 10.1097/00007691-200204000-00008
  • Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients, Marquet, Pierre, Pouche, Lucie, Youdarene, Rym, Monchaud, Caroline, Saint-Marcoux, Franck, Woillard, Jean-Baptiste, Pharmacological Research, 2015, 10.1016/j.phrs.2015.07.012
  • Simultaneous evaluation of six human glucuronidation activities in liver microsomes using liquid chromatography-tandem mass spectrometry, Picard, Nicolas, Marquet, Pierre, Sauvage, Francois-Ludovic, Rouguieg-Malki, Koukeb, Gagez, Anne-Laure, Analytical Biochemistry, 2012, 10.1016/j.ab.2012.04.031
  • COMPARISON OF 2-COMPARTMENT AND 3-COMPARTMENT MODELS FOR THE BAYESIAN-ESTIMATION OF METHOTREXATE PHARMACOKINETICS, LACHATRE, G, MERLE, L, MARQUET, P, ROULLET, B, DEBORD, J, SABOT, C, International Journal of Clinical Pharmacology and Therapeutics, 1995
  • Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients, Picard, Nicolas, Marquet, Pierre, Ali, Amany Mohamad, Thabet, Romany Helmy, Woillard, Jean-Baptiste, El Desoky, Ehab S., Hareedy, Mohammad Salem, Pharmacogenomics, 2015, 10.2217/PGS.15.62
  • Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcyRIII+ innate immune cells in rejection, Naesens M, Koshy P, Gwinner W, Franken A, Eloudzeri M, Vusser KD, Smet FD, Debyser T, Becker JU, Anglicheau D, Antoranz A, Herck YV, Callemeyn J, Lamarthée B, 2022, 10.1101/2022.07.07.22276374
  • EXPRESSION OF HLA CLASS I AND II MOLECULES ON THE DIFFERENT COMPOUNDS OF THE UTERUS, Gauthier, Tristan, Marquet, Pierre, Aubard, Yves, Piver, Pascal, Ribes, Romain, Essig, Marie, Guillaideau, Angerlique, Filloux, Matthieu, Pacha, Adam Fodil, Drouet, Mireille, Tissue Antigens, 2015
  • Contribution of CYP 3A4 and CYP 2D6 in loratadine metabolism in vitro, Marquet, P., Boughattas, N. A., Sauvage, F. L., Picard, N., Dridi, D., Fundamental & Clinical Pharmacology, 2007
  • A LC-MS/MS Method for the Simultaneous Evaluation of Human Glucuronidation Enzyme Activities using an in vitro Cocktail Approach, Marquet, P., Sauvage, F-L., Picard, N., Rouguieg, K., Therapeutic Drug Monitoring, 2009
  • Cyclosporin proficiency testing program: summary and analysis of french laboratories' results, Vassault, A, Holt, DW, Johnston, A, Meninat, F, Billaud, E, Perrin, A, Marquet, P, Annales De Biologie Clinique, 1999
  • Endogenous Metabolites-Mediated Communication Between OAT1/OAT3 and OATP1B1 May Explain the Association Between SLCO1B1 SNPs and Methotrexate Toxicity., Barin-Le Guellec C, Marquet P, Andrès CR, Choquet S, Gyan E, Berthelot A, Woillard JB, Muhrez K, Martinez D, Clinical pharmacology and therapeutics, 2018, 10.1002/cpt.1008
  • Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation., , European journal of clinical pharmacology, 2019, 10.1007/s00228-019-02716-y
  • PESTICIDE-RESIDUE DETERMINATION IN HONEY AND APPLES BY HPLC AND GC, LACHATRE, G, DAGUET, JL, DEBORD, J, MARQUET, P, LOTFI, H, DREYFUSS, MF, Analusis, 1994
  • Donor P-gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long-Term Follow-Up, Marquet, P., Le Meur, Y., Drouet, M., Essig, M., Munteanu, E., Guillaudeau, A., Rousseau, A., Picard, N., Rerolle, J-P, Woillard, J-B, Clinical Pharmacology & Therapeutics, 2010, 10.1038/clpt.2010.62
  • [Perinatal pharmacology of opiates]., Marquet, P, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2000, 10.1016/S0929-693X(00)80074-3
  • Pharmacokinetic Therapeutic Drug Monitoring of Advagraf in More Than 500 Adult Renal Transplant Patients, Using an Expert System Online, Woillard, J. B., Essig, M., Cassuto, E., Moulin, B., Kamar, N., Etienne, I., Rerolle, J. P., Saint-Marcoux, F., Monchaud, C., Bedu, A., Marquet, P., Therapeutic Drug Monitoring, 2018, 10.1097/ftd.0000000000000503
  • ACTIVATED NATURAL KILLER CELL TRANSCRIPTS PREDICT GRAFT OUTCOME IN KIDNEY TRANSPLANTATION: THE BIOMARGIN STUDY, Naesens, M., Marquet, P., Essig, M., Gwinner, W., Anglicheau, D., Gazut, S., Yazdani, S., Transplant International, 2017
  • Ribavirin therapeutic drug monitoring: why, when and how?, French Ribavirin Grp OPTIRIB, Marquet, Pierre, Gagnieu, Marie-Claude, Babany, Gerard, Loustaud-Ratti, Veronique, Stanke-Labesque, Francoise, Fundamental & Clinical Pharmacology, 2010, 10.1111/j.1472-8206.2009.00778.x
  • Post-mortem redistribution of three beta-blockers in the rabbit, Marquet, P, Lachatre, G, Leonetti, G, Feuerstein, M, Dupuis, C, Gaulier, JM, Pelissier-Alicot, AL, International Journal of Legal Medicine, 2006, 10.1007/s00414-005-0022-5
  • Current role of LC-MS in therapeutic drug monitoring, Marquet, Pierre, Sauvagge, Francois-Ludovic, Saint-Marcoux, Franck, Analytical and Bioanalytical Chemistry, 2007, 10.1007/s00216-007-1320-1
  • New rave drugs: Ketamine and prolintane, Lachatre, G, Marquet, P, Pradeille, JL, Canal, M, Gaulier, JM, Acta Clinica Belgica, 2002
  • Case study of neonates born to mothers undergoing buprenorphine maintenance treatment, Kintz, P, Lachatre, G, Gaulier, JM, Lavignasse, P, Marquet, P, Buprenorphine Therapy of Opiate Addiction, 2002
  • Uterus tolerance to extended cold ischemic storage after auto-transplantation in ewes, Gauthier, T., Piccardo, A., Marquet, P., Yardin, C., Terro, F., Couquet, C., Lachatre, D., Mesturoux, L., Tholance, Y., Ponsonnard, S., Tricard, J., European Journal of Obstetrics & Gynecology and Reproductive Biology, 2017, 10.1016/j.ejogrb.2017.05.013
  • Fetal growth restriction, low birth weight, and preterm birth: Effects of active or passive smoking evaluated by maternal expired CO at delivery, impacts of cessation at different trimesters, Yves Aubard, Pierre Marquet, Tristan Gauthier, Amal Jamee, Michel-Henri Delcroix, Conchita Delcroix-Gomez, Tobacco Induced Diseases, 2022, 10.18332/tid/152111
  • Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis, Marquet, Pierre, Lachatre, Gerard, Gaulier, Jean-Michel, Sauvage, Francois-Ludovic, Clinical Chemistry, 2008, 10.1373/clinchem.2008.105478
  • Evaluation of Experiences with Immunosuppressive Drugs in Transplantation: Validation of the MESI Scale in French, Monchaud, C., Marquet, P., Debette-Gratien, M., Pison, C., Epailly, E., Etienne, I., Essig, M., Knoop, C., Woillard, J. B., Villeneuve, C., Pharmaceutical Medicine, 2017, 10.1007/s40290-017-0207-5
  • Development and Evaluation of a Simulation Procedure to Take Into Account Various Assays for the Bayesian Dose Adjustment of Tacrolimus, Marquet, Pierre, Rousseau, Annick, Rostaing, Lionel, Kamar, Nassim, Labalette, Myriam, Parant, Francois, Debord, Jean, Saint-Marcoux, Franck, Therapeutic Drug Monitoring, 2011, 10.1097/FTD.0b013e31820d6ef7
  • Liquid chromatography electrospray mass spectrometry multiresidue determination of pesticides in apples and pears, Lachatre, G, Marquet, P, Vignaud, M, Daguet, JL, Dreyfuss, MF, Lacassie, E, Journal of Chromatography a, 1999, 10.1016/S0021-9673(98)00871-1
  • Proximal Tubular Dysfunction Is Common After the First Year of Kidney Transplantation, Essig, M., Marquet, P., Aldigier, J. -C., Bodeau, S., Marin, B., Saint-Marcoux, F., Allard, J., Ensergueix, G., American Journal of Transplantation, 2015
  • Sum of peak intensities outperforms peak area integration in iTRAQ protein expression measurement by LC-MS/MS using a TripleTOF 5600+ platform., , Bioscience Reports, 2019, 10.1042/bsr20190904
  • Analytical multi-site evaluation of the architect cyclosporine assay, Wonigeit, Kurt, Aimo, Giuseppe, Marquet, Pierre, Wallemacq, Pierre, Young, Julianna, Schmidt, Ed, Rosiere, Thomas K., Berg, Keith G., Maine, Greorv T., American Journal of Transplantation, 2008
  • Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study, Silvente-Poirot, S., Poirot, M., Roche, H., Samadi, M., Marquet, P., Chatelut, E., Arellano, C., Voisin, M., Zerbinati, C., Filleron, T., Iuliano, L., Dalenc, F., Journal of Steroid Biochemistry and Molecular Biology, 2017, 10.1016/j.jsbmb.2016.06.010
  • Contribution of the Different UDP-Glucuronosyltransferase (UGT) Isoforms to Buprenorphine and Norbuprenorphine Metabolism and Relationship with the Main UGT Polymorphisms in a Bank of Human Liver Microsomes, Marquet, Pierre, Gaulier, Jean-Michel, Sauvage, Francois-Ludovic, Picard, Nicolas, Rouguieg, Koukeb, Drug Metabolism and Disposition, 2010, 10.1124/dmd.109.029546
  • FP7 BIOMARGIN: URINARY PROTEIN BIOMARKERS OF RENAL GRAFT INJURIES IN KIDNEY ALLOGRAFT RECIPIENTS, Mertens, I., Marquet, P., Essig, M., Anglicheau, D., Gwinner, W., Naesens, M., Baggerman, G., Schildermans, K., Willems, H., Transplant International, 2017
  • Modulation of Monocyte Response by MicroRNA-15b/106a/374a During Antibody-mediated Rejection in Kidney Transplantation., Anglicheau D, Rabant M, Cagnard N, Aouni L, Morin L, Ménager M, Garcia-Paredes V, Sauvaget V, Benon A, Von Tokarski F, Van Loon E, Gazut S, Lamarthée B, Tinel C, Transplantation, 2023, 10.1097/tp.0000000000004393
  • Pharmacodynamic Monitoring of mTOR Inhibitors, , Therapeutic Drug Monitoring, 2019, 10.1097/ftd.0000000000000616
  • Relationship between exposure to calcineurin inhibitors over the first year after kidney transplantation and infections: a cohort study, Monchaud, C., Marquet, P., Essig, M., Kamar, N., Merville, P., Bouchet, S., Lacroix, I., Coubret, A., Laroche, M. L., Woillard, J. B., Villeneuve, C., Trouche-Estival, B., Fundamental & Clinical Pharmacology, 2017
  • Untitled, Marquet, P, Rousseau, A, Saint-Marcoux, F, Therapeutic Drug Monitoring, 2006, 10.1097/01.ftd.0000188016.36982.35
  • Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study, Marquet, Pierre, Samuel, Didier, Sebagh, Mylene, Sinnasse-Raymond, Gilles, Taguieva, Naila, Duvoux, Christophe, Pageaux, Georges-Philippe, Salame, Ephrem, Calmus, Yvon, Neau-Cransac, Martine, Leroy, Vincent, Radenne, Sylvie, Durand, Francois, Gugenheim, Jean, Rostaing, Lionel, Saliba, Faouzi, Transplantation, 2016, 10.1097/TP.0000000000001228
  • Higher exposure to mycophcnolic acid with sirohmus than with cyclosporine cotreatment, Paintaud, G, Marquet, P, Hary, L, Libert, F, le Guellec, C, Westeel, PF, Heng, AE, Le Meur, Y, Beneton, M, Lebranchu, Y, Buchler, M, Clinical Pharmacology & Therapeutics, 2005, 10.1016/j.clpt.2005.03.005
  • From small molecules to proteins: the same risks of misinterpretation of LC-MS/MS results, Gastinel, L. N., Marquet, P., Gagez, A. L., Sauvage, F. L., Therapeutic Drug Monitoring, 2011
  • Application of a gamma model of absorption to oral cyclosporin, Le Guellec, C, Lachatre, G, Buchler, M, Le Meur, Y, Harel, M, Risco, E, Debord, J, Clinical Pharmacokinetics, 2001, 10.2165/00003088-200140050-00004
  • Effect of Mycophenolate Acyl-Glucuronide on Human Recombinant Type 2 Inosine Monophosphate Dehydrogenase, Marquet, Pierre, Picard, Nicolas, Gensburger, Olivier, Clinical Chemistry, 2009, 10.1373/clinchem.2008.113936
  • High-throughput sequencing defines donor and recipient HLA B-cell epitope frequencies for prospective matching in transplantation., , Communications biology, 2021, 10.1038/s42003-021-01989-3
  • Untargeted screening of urinary peptides with liquid chromatography coupled to hybrid linear-ion trap tandem mass spectrometry, Marquet, Pierre, Gastinel, Louis Noel, Sauvage, Francois-Ludovic, Journal of Chromatography a, 2012, 10.1016/j.chroma.2012.04.006
  • General unknown screening procedure using liquid chromatography-linear ion trap tandem mass spectrometry: Application to a tricky case, Marquet, Pierre, Lachatre, Gerard, Gaulier, Jean-Michel, Saint-Marcoux, Franck, Sauvage, Francois-Ludovic, Therapeutic Drug Monitoring, 2007
  • Impairing temozolomide resistance driven by glioma stem-like cells with adjuvant immunotherapy targeting O-acetyl GD2 ganglioside., , International journal of cancer, 2019, 10.1002/ijc.32533
  • Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters, Marquet, Pierre, Giacomini, Kathleen M., Yee, Sook Wah, Lamoureux, Fabien, Levoir, Laure, Picard, Nicolas, Xenobiotica, 2011, 10.3109/00498254.2011.573882
  • Effect of a new functional CYP3A4 polymorphism on sirolimus in vitro metabolism and kidney transplant recipients trough levels, Picard, N., Marquet, P., Coste, S., Rostaing, L., Kamar, N., Woillard, J. B., Fundamental & Clinical Pharmacology, 2012
  • Assessment of pesticide exposure in vineyard workers, Brochard, P, Marquet, P, Dulaurent, S, Ducamp, S, Rolland, P, Balid, I, Epidemiology, 2002
  • [A specific dosage method for the analysis of 24 antidepressants using gas chromatography-mass spectrometry (GC/SM)]., Lachatre, G, Marquet, P, Gaulier, J M, Ragot, S, Lacassie, E, Acta clinica Belgica, 1999
  • Activities of clinical pharmacologists across Europe: A survey by the European association of clinical pharmacology and therapeutics, Aranzazu Sancho-Lopez, Joaquin Sáez-Peñataro, Emilie Jouanjus, Pierre Marquet, European Journal of Clinical Pharmacology, 2024, 10.1007/s00228-024-03657-x
  • Effect of calcineurine and mTOR inhibitors on the intestinal absorption of mycophenolic acid, Marquet, Pierre, Sauvage, Francois-Ludovic, Picard, Nicolas, Boussera, Belkacem, Therapeutic Drug Monitoring, 2007
  • Clinical Pharmacokinetics and Bayesian Estimators for the Individual Dose Adjustment of a Generic Formulation of Tacrolimus in Adult Kidney Transplant Recipients, Jean Debord, Jean-Baptiste Woillard, Nicolas Picard, Antoine Thierry, Isabelle Etienne, Hakim Mazouz, Matthias Buchler, Jean-Philippe Rérolle, Caroline Monchaud, Alexandre Destère, Pierre Marquet, Clinical Pharmacokinetics, 2021, 10.1007/s40262-020-00959-y
  • Phase II metabolites of mycophenolic acid: In vitro/in vivo characterization and pharmacokinetics in renal transplants, Marquet, P, Ratanasavangh, D, Le Meur, Y, Rousseau, A, Premaud, A, Picard, N, Therapeutic Drug Monitoring, 2003
  • Drug-resistant cytomegalovirus in transplant recipients: a French cohort study, French CMV Resistance Survey Study, Alain, Sophie, Turlure, Pascal, Lebranchu, Yvon, Pillet, Sylvie, Germi, Raphaelle, Cotin, Sebastien, Rerolle, Jean-Philippe, Essig, Marie, Saint Marcoux, Franck, Rostaing, Lionel, Mengelle, Catherine, Merville, Pierre, Garrigue, Isabelle, Mazeron, Marie-Christine, Garnier-Geoffroy, Francoise, Hantz, Sebastien, Journal of Antimicrobial Chemotherapy, 2010, 10.1093/jac/dkq368
  • Association analysis between polymorphisms in proteins of the m-TOR signaling pathway and sirolimus adverse effects in renal transplantation, Picard, N., Rostaing, L., Marquet, P., Rousseau, A., Kamar, N., Woillard, J. B., Therapeutic Drug Monitoring, 2011
  • A double-absorption pharmacokinetic model for mycophenolate in de novo renal transplant patients, Marquet, P, Toupance, O, Le Meur, Y, Hoizey, G, Rousseau, A, Debord, J, Premaud, A, Therapeutic Drug Monitoring, 2003
  • LC-MS/MS screen for xenobiotics and metabolites., Marquet, Pierre, Sauvage, Francois-Ludovic, Methods in molecular biology (Clifton, N.J.), 2012, 10.1007/978-1-61779-934-1_11
  • High-performance liquid chromatographic determination of tianeptine in plasma applied to pharmacokinetic studies, Lachatre, G, Desroches, R, Lacassie, E, Marquet, P, Gaulier, JM, Journal of Chromatography B, 2000, 10.1016/S0378-4347(00)00368-6
  • Statistics of MMF dose adjustment on ISBA, a free website for dose adjustment of immunosuppressive drugs, Marquet, P., Sequier, G., Canal, M., Tribut, O., Hoizey, G., Debord, J., Saint-Marcoux, F., Therapeutic Drug Monitoring, 2007
  • The scientific basis of rational prescribing. A guide to precision clinical pharmacology based on the WHO 6-step method., , European journal of clinical pharmacology, 2020, 10.1007/s00228-020-03044-2
  • Sirolimus population pharmacokinetic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients, Marquet, Pierre, Le Meur, Yann, Toupance, Olivier, Rerolle, Jean-Philippe, Hoizey, Guillaume, Rousseau, Annick, Djebli, Nassim, Clinical Pharmacokinetics, 2006, 10.2165/00003088-200645110-00007
  • Bupreuorphihe-related deaths, Marquet, P, Kintz, P, Buprenorphine Therapy of Opiate Addiction, 2002
  • Toward a robust tool for pharmacokinetic-based personalization of treatment with tacrolimus in solid organ transplantation: A model-based meta-analysis approach., , British journal of clinical pharmacology, 2019, 10.1111/bcp.14110
  • Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring, Marquet, P, Lachatre, G, Le Meur, Y, Rousseau, A, Premaud, A, Therapeutic Drug Monitoring, 2004
  • Comparison of dose proposed by an a priori population pharmacokinetic tool with clinician empirical dosing for vancomycine in premature neonates, Woillard, J. B., Marquet, P., Guigonis, V., Casagrande, K., Woloch, C., Saint-Marcoux, F., Grine, J., Fourgeaud, J., Fundamental & Clinical Pharmacology, 2016
  • Relationship between psychotropic drugs and thyroid function: A review (vol 149, pg 127, 1998), Lachatre, G, Buxeraud, J, Raby, C, Rousseau, A, Marquet, P, Sauvage, MF, Toxicology and Applied Pharmacology, 1998, 10.1006/taap.1998.8531
  • Nonparametric Approach for Population Pharmacokinetic Study of Tacrolimus in Heart Transplant Patients, Saint-Marcoux, F., Marquet, P., Fruit, D., Woillard, J. B., Youdarene, R., Therapeutic Drug Monitoring, 2013
  • Is LC-MS suitable for a comprehensive screening of drugs and poisons in clinical toxicology?, Marquet, P, Therapeutic Drug Monitoring, 2002, 10.1097/00007691-200202000-00020
  • Comment on "Population Pharmacokinetics of Mycophenolic Acid: An Update"., Marquet P, Debord J, Woillard JB, Clinical pharmacokinetics, 2018, 10.1007/s40262-018-0687-9
  • A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients, Marquet, Pierre, Le Meur, Yannick, Rousseau, Annick, Premaud, Aurelie, Picard, Nicolas, British Journal of Clinical Pharmacology, 2006, 10.1111/j.1365-2125.2006.02509.x
  • Population analysis and covariates influencing the pharmacokinetics of mycophenolic acid in renal transplant recipients, Rousseau, A, Marquet, P, Hoizey, G, Toupance, O, Szelag, JC, Le Meur, YPA, Therapeutic Drug Monitoring, 2005
  • A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators, , Clinical Pharmacokinetics, 2018, 10.1007/s40262-018-0646-5
  • In vitro study of mycophenolic acid glucuronidation, Marquet, P, Picard, N, Drug Metabolism and Disposition, 2004, 10.1124/dmd.104.001982
  • Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation, Rousseau, Annick, Marquet, Pierre, Kamar, Nassim, Urien, Saik, Saint-Marcoux, Franck, Woillard, Jean-Baptiste, Premaud, Aurelie, Rostaing, Lionel, Benkali, Khaled, Clinical Pharmacokinetics, 2010
  • Determination of buprenorphine and norbuprenorphine in whole blood by liquid chromatography mass spectrometry, Lachatre, G, Dupuy, JL, Lotfi, H, Verneuil, B, Marquet, P, Hoja, H, Journal of Analytical Toxicology, 1997
  • Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer: a case control study, Picard, N., Marquet, P., Rouguieg-Malki, K., Thalamas, C., Guimbaud, R., Smith, D., Pariente, A., Terrebonne, E., Tubiana-Mathieu, N., Postil, D., Woillard, J. B., Falkowski, S., Bmc Cancer, 2017, 10.1186/s12885-017-3728-0
  • Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation, EPIGREN Study Grp, Rousseau, Annick, Marquet, Pierre, Fruit, Dorothee, Bouchet, Stephane, Lacroix, Isabelle, Coubret, Anne, Kamar, Nassim, Merville, Pierre, Essig, Marie, Laroche, Marie-Laure, Villeneuve, Claire, Transplantation, 2016, 10.1097/TP.0000000000000846
  • Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients., , British journal of clinical pharmacology, 2020, 10.1111/bcp.14261
  • Fatal intoxication following self-administration of a massive dose of buprenorphine, Lachatre, G, Dupuy, JL, Lacassie, E, Marquet, P, Gaulier, JM, Journal of Forensic Sciences, 2000
  • Determination of three beta-blockers in biofluids and solid tissues by liquid chromatography-electrospray-mass spectrometry, Lachatre, U, Marquet, P, Pelissier-Alicot, AL, Gaulier, JM, Dupuis, C, Journal of Analytical Toxicology, 2004
  • Towards therapeutic drug monitoring of everolimus? Results of an exploratory study of the dose-exposure relationships, Woillard, J. B., Marquet, P., Tubiana-Mathieu, N., Picard, N., Laroche, M. L., Monchaud, C., Saint-Marcoux, F., Falkowski, S., Deppenweiler, M., Fundamental & Clinical Pharmacology, 2017
  • Analytical aspects of volatile substance abuse (VSA), Lachatre, G, Marquet, P, Sayer, H, Faict, T, Tonnay, V, Gaulier, JM, Journal of Forensic Sciences, 2003
  • Feasibility of Ribavirin Therapeutic Drug Monitoring in Hepatitis C, Marquet, Pierre, Babany, Gerard, Gagnieu, Marie-Claude, Jourdil, Jean-Francois, Stanke-Labesque, Francoise, Sauvage, Francois-Ludovic, Therapeutic Drug Monitoring, 2009
  • Therapeutic education as a tool to improve patient-reported and clinical outcomes after renal transplantation: results of the EPHEGREN multicenter retrospective cohort study., Monchaud C, Marquet P, Thierry A, Büchler M, Kamar N, Esposito L, Etienne I, Westeel PF, Couzi L, Rerolle JP, Villeneuve C, Transplant international : official journal of the European Society for Organ Transplantation, 2021, 10.1111/tri.14127
  • Voriconazole clearance estimation using pharmacokinetic population modeling, Woillard, J. B., Gandia, P., Marquet, P., Seraissol, P., Laffont, M. A., Lamoureux, F., Metsu, D., Fundamental & Clinical Pharmacology, 2015
  • Pharmacokinetics of Mycophenolate Mofetil (MMF) in Lung Transplantation: Comparison with Renal Transplantation, Rousseau, A., Marquet, P., Estenne, M., Knoop, C., Guillemain, R., Stern, M., Dromer, C., Reynaud-Gaubert, M., Kessler, R., Pison, C., Premaud, A., Monchaud, C., de Winter, B. C. M., Journal of Heart and Lung Transplantation, 2011
  • Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism, Marquet, P, Le Meur, Y, Premaud, A, Ratanasavanh, D, Picard, N, Drug Metabolism and Disposition, 2005, 10.1124/dmd.104.001651
  • Special issue - 40th Annual International Meeting of the International Association of Forensic Toxicologists - Preface, Organising Comm, Kintz, P, Marquet, P, Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 2003, 10.1016/S1570-0232(03)00136-3
  • Pharmacological determinants of post-transplant lymphoproliferative disease (PTLD): feasibility of a large case-control study, Marquet, P., Essig, M., Rerolle, J., Roussel, H., Rousseau, A., Caillard, S., Stojanova, J., Fundamental & Clinical Pharmacology, 2011
  • Study of the association of glucuroconjugation enzyme polymorphism and xenobiotic transport proteins in patients suffering from colorectal cancer, Marquet, P., Durand, K., Labrousse, F., Rousseau, A., Picard, N., Rouguieg, W., Bulletin Du Cancer, 2008
  • Health research and innovation: Can we optimize the interface between startups/pharmaceutical companies and academic health care institutions or not?, , Therapie, 2019, 10.1016/j.therap.2019.11.010
  • The Role of Organic Anion-Transporting Polypeptides and Their Common Genetic Variants in Mycophenolic Acid Pharmacokinetics, Marquet, P., Giacomini, K. M., Le Meur, Y., Lebranchu, Y., Woillard, J-B, Yee, S. W., Picard, N., Clinical Pharmacology & Therapeutics, 2010, 10.1038/clpt.2009.205
  • Ultrafast Measurement of Metformin in the Clinical Setting Using Probe Electrospray Ionization Mass Spectrometry., Saint-Marcoux F, Dulaurent S, Marquet P, Lamoureux F, Bodeau S, El Balkhi S, Griffeuille P, Journal of analytical toxicology, 2023, 10.1093/jat/bkac034
  • Special issue: TIAFT 2002 - Preface, Kintz, P, Marquet, P, Forensic Science International, 2003, 10.1016/S0379-0738(03)00041-0
  • Analytical multi-site evaluation of the Abbott ARCHITECT Cyclosporine assay, Wonigeit, K., Marquet, P., Aimo, G., Schmid, R., Young, J., Schmidt, E., Berg, K., Ait-Youcef, H., Wallemacq, P., Maine, G. T., Clinical Chemistry, 2008
  • Screening procedure for 21 amphetamine-related compounds in urine using solid-phase microextraction and gas chromatography mass spectrometry, Lachatre, G, Lacassie, E, Fauconnet, AL, Marquet, P, Battu, C, Journal of Chromatographic Science, 1998
  • Identification of acepromazine in hair: An illustration of the difficulties encountered in investigating drug-facilitated crimes, Lachatre, Gerard, Marquet, Pierre, Saint-Marcoux, Franck, Pauthier, Helene, Sauvage, Francois-Ludovic, Gaulier, Jean-Michel, Journal of Forensic Sciences, 2008, 10.1111/j.1556-4029.2008.00706.x
  • Influence of UGT1A9*3 and UGT2B7 (G-840A) polymorphisms on MPA metabolism in renal transplant recipients, Marquet, P, Rousseau, A, Szelag, JC, Le Meur, Y, Picard, N, Djebli, N, Therapeutic Drug Monitoring, 2005, 10.1097/00007691-200504000-00154
  • MPA EXPOSURE IN PATIENTS WITH EARLY STEROID WITHDRAWAL: COMPARISON BETWEEN TWO MMF BASED IMMUNOSUPPRESSIVE REGIMENS, CONCENTRATION-CONTROLLED VERSUS FIXED DOSE, Marquet, P., Tagieva, N., Rouanet, S., Thervet, E., Dantal, J., Bayle, F., Vrtovsnik, F., Mousson, C., Glotz, D., Kessler, M., Lebranchu, Y., Tricot, L., Rondeau, E., Kamar, N., Le Meur, Y., Transplant International, 2009
  • Determination of colchicine in biological fluids by liquid chromatography mass spectrometry with pneumatically assisted electrospray ionization., Lachatre, G, Dreyfuss, MF, Dupuy, JL, Lotfi, H, Verneuil, B, Marquet, P, Hoja, H, Analusis, 1996
  • Real life experience of mycophenolate mofetil monotherapy in liver transplant patients., , Clinics and research in hepatology and gastroenterology, 2020, 10.1016/j.clinre.2020.04.017
  • New perspectives for the therapeutic drug monitoring of tacrolimus: Quantification in volumetric DBS based on an automated extraction and LC-MS/MS analysis., Monchaud C, Saint-Marcoux F, Marquet P, Debette-Gratien M, Rerolle JP, El Balkhi S, Tafzi N, Rosé G, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2023, 10.1016/j.jchromb.2023.123721
  • Evaluation of an improved general unknown screening procedure using liquid-chromatography-electrospray-mass spectrometry by comparison with gas chromatography and high-performance liquid-chromatography-diode array detection, Marquet, P, Lachatre, G, Saint-Marcoux, F, Journal of the American Society For Mass Spectrometry, 2003, 10.1016/S1044-0305(02)00801-2
  • In the post-APOMYGRE era: ISBA, a free website for Bayesian dose adjustment of immunosuppressive drugs, Grp Suivi Therapeut Pharmacol SEPT, Marquet, P., Sequier, G., Canal, M., Tribut, O., Hoizey, G., Debord, J., Saint-Marcoux, F., Fundamental & Clinical Pharmacology, 2007
  • First 6-month report of the longitudinal PHACS study (Pharmacology and Hormonotherapy (HT) for Adjuvant breast Cancer (BC) Study, NCT01127295), Filleron, T., Chatelut, E., Evrard, A., Marquet, P., Pinguet, F., Robert, J., Mauries, V., Massabeau, C., Lavau-Denes, S., Laharie-Mineur, H., Ferrer, C., Franck, D., Dohollou, N., Molnar-Stanciu, D., Dalenc, F., Suc, E., Jacot, W., Debled, M., Venat-Bouvet, L., Roche, H., Cancer Research, 2018
  • How to improve clinical research performances in France?, Unger, Philippe, Trinquet, Francoise, Thuillez, Christian, Rossignol, Patrick, Reynier, Jean Charles, Rascol, Olivier, Postaire, Eric, Pathak, Atul, Ogier, Emmanuel, Marquet, Pierre, Marey, Christine, Maisonneuve, Pascale, Le Thiec, Francoise, Le Coent, Remi, Joubert, Jean Michel, Gueyffier, Francois, Gaultier, Claude, Dubray, Claude, Devilliers, Elisabeth, Deregnaucourt, Jean, Decousus, Herve, Cournot, Antoine, Bey, Pierre, Behier, Jehan Michel, Ballet, Francois, Round Table No. 4, Giens XXIII, Pletan, Yannick, Diebolt, Vincent, Therapie, 2008, 10.2515/therapie:2008045
  • Population Pharmacokinetic Model and Bayesian Estimator for Mycophenolate Mofetil (MMF) in Lung Transplantation, Rousseau, A., Estenne, M., Knoop, C., Guillemain, R., Stern, M., Dromer, C., Reynaud-Gaubert, M., Kessler, R., Pison, C., Premaud, A., Monchaud, C., de Winter, B. C. M., Marquet, P., American Journal of Transplantation, 2011
  • Association analysis between m-TOR, p70S6k and Raptor polymorphisms and sirolimus adverse events in renal transplant patients, Marquet, P., Rostaing, L., Rousseau, A., Picard, N., Kamar, N., Woillard, J., Fundamental & Clinical Pharmacology, 2011
  • Ribavirin: Past, present and future., Carrier, Paul, Rousseau, Annick, Sautereau, Denis, Marquet, Pierre, Alain, Sophie, Jacques, Jeremie, Debette-Gratien, Marilyne, Loustaud-Ratti, Veronique, World journal of hepatology, 2016, 10.4254/wjh.v8.i2.123
  • INDIVIDUALIZING TRANSPLANT THERAPY, Asberg, A., Marquet, P., Individualized Drug Therapy for Patients: Basic Foundations, Relevant Software and Clinical Applications, 2017, 10.1016/b978-0-12-803348-7.00016-2
  • Adaptation of the implementation of good clinical practices depending on the characteristics of some research, Participants Table Ronde Giens 21, Best, Nicolas, Courcier-Duplantier, Soizic, Bertoye, Pierre-Henri, Therapie, 2006, 10.2515/therapie:2006052
  • Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: Comparison between cystic fibrosis and other conditions, Estenne, M, Marquet, P, Rousseau, A, Kovarik, JM, De Backer, M, Thiry, P, Vervier, I, Knoop, C, Transplantation, 2003, 10.1097/01.TP.0000076473.71399.26
  • Advagraf((R)), a once-daily prolonged release tacrolimus formulation, in kidney transplantation: literature review and guidelines from a panel of experts, Marquet, Pierre, Grimbert, Philippe, Audard, Vincent, Mariat, Christophe, Buron, Fanny, Moulin, Bruno, Caillard, Sophie, Transplant International, 2016, 10.1111/tri.12674
  • Pharmacokinetics and Therapeutic Drug Monitoring of anticancer agents, Rousseau, Annick, Marquet, Pierre, Bulletin Du Cancer, 2008, 10.1684/bdc.2008.0725
  • Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation, Marquet, P, Dantoine, T, Debord, J, David, OJ, Leger, F, Rousseau, A, Monchaud, C, European Journal of Clinical Pharmacology, 2003, 10.1007/s00228-003-0559-5
  • Development and validation of a peripheral blood mRNA assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study., , EBioMedicine, 2019, 10.1016/j.ebiom.2019.07.028
  • Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5, Marquet, P, Premaud, A, Cresteil, T, Picard, N, Therapeutic Drug Monitoring, 2004, 10.1097/00007691-200412000-00004
  • Impact of NR1I2 (PXR) polymorphisms on tacrolimus pharmacokinetics in renal transplant patients, Le Meur, Yannick, Marquet, Pierre, Villemain, Florence, Toupance, Olivier, Hoizey, Guillaume, Rerolle, Jean-Philippe, Picard, Nicolas, Rousseau, Annick, Benkali, Khaled, American Journal of Transplantation, 2008
  • Machine learning-supported interpretation of kidney graft elementary lesions in combination with clinical data, Pierre Marquet, Maarten Naesens, Priyanka Koshy, Marion Rabant, Dany Anglicheau, Jan-Hinrich Braesen, Wilfried Gwinner, Jean-Baptiste Woillard, Marc Labriffe, 2021, 10.1101/2021.09.17.21263552
  • Multiresidue determination method for organophosphorus pesticides in serum and whole blood by gas chromatography-mass-selective detection, Lachatre, G, Daguet, JL, Marquet, P, Gaulier, JM, Dreyfuss, MF, Lacassie, E, Journal of Chromatography B, 2001, 10.1016/S0378-4347(01)00211-0
  • Ingestion of high-dose buprenorphine by a 4 year-old child, Lachatre, G, Marquet, P, Monceaux, F, Charvier, F, Gaulier, JM, Journal of Toxicology-Clinical Toxicology, 2004, 10.1081/CLT-200042470
  • The Effect of Genetic Variations in Cytochromes P450 3A, the P450 Oxydoreductase (POR) and the Nuclear Receptor PPARA on Sirolimus In Vitro Metabolism, Trough Levels and Adverse Events in Kidney Transplant Recipients, Picard, N., Marquet, P., Rostaing, L., Coste, S., Kamar, N., Woillard, J. B., Therapeutic Drug Monitoring, 2013
  • European Society for Organ Transplantation Advisory Committee Recommendations on Generic Substitution of Immunosuppressive Drugs, ESOT Advisory Comm Generic, van Gelder, Teun, Transplant International, 2011
  • Simultaneous determination of lidocaine and bupivacaine in human plasma: Application to pharmacokinetics, Lachatre, G, Feiss, P, BenRhaiem, M, Marquet, P, Dreyfuss, MF, Debord, J, Lotfi, H, Therapeutic Drug Monitoring, 1997, 10.1097/00007691-199704000-00007
  • Identification of the UDP-Glueuronosyltransferase (UGT) Isoforms involved in Buprenorphine Glucuronidation and Evaluation of the Inhibitory Potential of this Drug on UGTs, Picard, N., Marquet, P., Comte, J-H., Sauvage, F-L., Rouguieg, K., Therapeutic Drug Monitoring, 2009
  • Metabolic pathways involved in the activation of organophosphothioate pesticides, Marquet, P, Lachatre, G, Dulaurent, S, Picard, N, Teilhet, E, Therapeutic Drug Monitoring, 2005
  • Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First Year Post-Liver Transplantation., , Transplantation, 2020, 10.1097/tp.0000000000003384
  • Tacrolimus Exposure Prediction Using Machine Learning., , Clinical pharmacology and therapeutics, 2020, 10.1002/cpt.2123
  • A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil, Marquet, P, Le Guellec, C, Hoizey, G, Lebranchu, Y, Toupance, O, Le Meur, Y, Rousseau, A, Debord, J, Premaud, A, Clinical Pharmacokinetics, 2005
  • Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis, Lachatre, G, Merle, L, Treves, R, Marquet, P, Bertin, P, Sabot, C, Carpentier, N, Debord, J, International Journal of Clinical Pharmacology and Therapeutics, 1998
  • Decrease of serum paraoxonase activity in chronic renal failure and return to normal values after transplantation, Ardaillou, R, LerouxRobert, C, Merle, L, Lachatre, G, Marquet, P, Charmes, JP, Debord, J, Dantoine, T, Journal of the American Society of Nephrology, 1996
  • Performance of the New Mycophenolate Assay Based on IMPDH Enzymatic Activity for Pharmacokinetic Investigations and Setup of Bayesian Estimators in Different Populations of Allograft Recipients, Debord, Jean, Domke, Ingrid, Tiberi, Marco, Lebranchu, Yvon, Knoop, Christiane, Jaqz-Aigrain, Evelyne, Sauvage, Francois-Ludovic, Premaud, Aurelie, Saint-Marcoux, Franck, Marquet, Pierre, Therapeutic Drug Monitoring, 2009
  • Multiresidue determination of pesticides in apples and pears by gas chromatography mass spectrometry, Lachatre, G, Marquet, P, Vignaud, M, Daguet, JL, Dreyfuss, MF, Lacassie, E, Journal of Chromatography a, 1998, 10.1016/S0021-9673(97)01305-8
  • Simultaneous determination of four anthracyclines and three metabolites in human serum by liquid chromatography-electrospray mass spectrometry, Dupuy, JL, Cardot, P, Gaulier, JM, Ragot, S, Marquet, P, Lachatre, F, Journal of Chromatography B, 2000, 10.1016/S0378-4347(99)00529-0
  • Population pharmacokinetics of cyclosporin in lung transplant patients: mixed-effect modeling and development of a Bayesian estimator using NONMEM, Marquet, P, Bernard, N, Estenne, M, Debord, J, Rousseau, A, Saint-Marcoux, F, Therapeutic Drug Monitoring, 2003
  • Functions of the Therapeutic Drug Monitoring (TDM) group of the French Society of Pharmacology, Marquet, P, Therapie, 2001
  • Multi-center evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus, Barnes, G, Wallemacq, P, Schmid, R, Fillee, C, Brunet, M, Streit, F, Mosso, R, Oellerich, M, Moscato, D, Marquet, P, Luthe, H, Gaulier, JM, Engelmayer, J, Moreton, M, Holt, D, Johnston, F, Wilson, D, Clinical Biochemistry, 2006, 10.1016/j.clinbiochem.2006.01.017
  • Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship, Woillard, J. B., Marquet, P., Venat-Bouvet, L., Tubiana-Mathieu, N., Laroche, M. L., Picard, N., Monchaud, C., Saint-Marcoux, F., Falkowski, S., Deppenweiler, M., Pharmacological Research, 2017, 10.1016/j.phrs.2017.04.029
  • Characterization of a new metabolic pathway for buprenorphine, Marquet, P, Cresteil, T, Picard, N, Therapeutic Drug Monitoring, 2003
  • Optimization of Vancomycin Initial Dose in Term and Preterm Neonates by Machine Learning., Woillard JB, Jacqz-Aigrain E, Labriffe M, Marquet P, Destere A, Ensuque P, Ponthier L, Pharmaceutical research, 2022, 10.1007/s11095-022-03351-6
  • Analyses of AUC(0-12) and C0 Compliances within Therapeutic Ranges in Kidney Recipients Receiving Cyclosporine or Tacrolimus., , Journal of clinical medicine, 2020, 10.3390/jcm9123903
  • Does CYP3A5 polymorphism influence everolimus intestinal and hepatic metabolism?, Marquet, P., Picard, N., Rouguieg-Malki, K., Fundamental & Clinical Pharmacology, 2010
  • Therapeutic Drug Monitoring of Everolimus: A Consensus Report, Marquet, Pierre, Thompson, Carol, Morris, Raymond G., Wallemacq, Pierre, Langman, Loralie J., Oellerich, Michael, Picard, Nicolas, Seger, Christoph, Masuda, Satohiro, Millan Lopez, Olga, Wieland, Eberhard, De Simone, Paolo, Barten, Markus J., Budde, Klemens, Brunet, Merce, Kunicki, Pawel K., van Gelder, Teun, Billaud, Eliane M., Holt, David W., Hesselink, Dennis A., Shipkova, Maria, Therapeutic Drug Monitoring, 2016
  • Lessons from Routine Dose Adjustment of Tacrolimus Based on Global Exposure in Renal Transplant Patients, Marquet, P., Woillard, J. B., Jurado, C., Saint-Marcoux, F., American Journal of Transplantation, 2012
  • Determination of N-acetylation phenotype using caffeine as a metabolic probe and high-performance liquid chromatography with either ultraviolet detection or electrospray mass spectrometry, Farinotti, R, Davrinche, C, Soursac, M, Marquet, P, Baud-Camus, F, Journal of Chromatography B, 2001, 10.1016/S0378-4347(01)00246-8
  • Estimation of drug exposure by machine learning based on simulations from published pharmacokinetic models: The example of tacrolimus., , Pharmacological research, 2021, 10.1016/j.phrs.2021.105578
  • Sensitive and specific determination of midazolam and 1-hydroxymidazolam in human serum by liquid chromatography-electrospray mass spectrometry, Lachatre, G, Francois, B, Dupuy, JL, Lacassie, E, Gaulier, JM, Baudin, O, Marquet, P, Journal of Chromatography B, 1999, 10.1016/S0378-4347(99)00340-0
  • How Tacrolimus Pharmacodynamics of the Patients in the Waiting List Could Influence Post Liver Transplantation Profile?, Marquet, Pierre, Woillard, Jean-Baptiste, Tourino, Cristina, Lens, Daniela, Gerona, Solange, Esperon, Patricia, Pouche, Lucie, Noceti, Ofelia M., Transplantation, 2016
  • Steroid-Free Regimen and Optimization of Mycophenolic Acid (MPA) Exposure in Liver Graft Recipients: Final Results of the Celleste Study, Kamar, N., Tagieva, N., Dur, C., Sebagh, M., Marquet, P., Vanlemmens, C., Hardwigsen, J., Dharancy, S., Pageaux, G. P., Duvoux, C., Altieri, M., Calmus, Y., Neau-Cransac, M., Leroy, V., Radenne, S., Gugenheim, J., Durand, F., Saliba, F., American Journal of Transplantation, 2012
  • Cost-effectiveness of mycophenolate mofetil monitoring and dose adjustment in kidney transplant recipients, Le Meur, Y., Hoizey, G., Compagnon, P., Hary, L., Venisse, N., Grima, M., Turcant, A., Debruyne, D., Saivin, S., Jacqz-Aigrain, E., Vergnenegre, A., Marquet, P., Laroche, M. L., Fundamental & Clinical Pharmacology, 2007
  • An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies, Rousseau, A., Essig, M., Marquet, P., Munteanu, E., Buchler, M., Thierry, A., Gatault, P., Filloux, M., Premaud, A., Plos One, 2017, 10.1371/journal.pone.0180236
  • New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs, Picard, Nicolas, Marquet, Pierre, Stojanova, Jana, Pouche, Lucie, Pharmacogenomics, 2016, 10.2217/pgs.15.169
  • LC-MS/MS systematic toxicological analysis: Comparison of MS/MS spectra obtained with different instruments and settings, Marquet, P, Lachatre, G, Jansen, R, Clinical Biochemistry, 2005, 10.1016/j.clinbiochem.2004.11.003
  • Controlled drug administration studies of high-dose buprenorphine in humans, Marquet, P, Kintz, P, Huestis, MA, Buprenorphine Therapy of Opiate Addiction, 2002
  • [Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects]., Marquet, P, Acta clinica Belgica, 1999
  • Native Urinary Peptides Identified as Biomarkers of Graft Lesions in Renal Transplant Recipients., Gastinel, L. N., Delahousse, M., Cassuto-Viguier, E., Bayle, F., Taguieva, N., Le Meur, Y., Gagez, A. -L., Marquet, P., American Journal of Transplantation, 2011
  • Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms, Saint-Marcoux, Franck, Marquet, Pierre, Essig, Marie, Alain, Sophie, Tafzi, Naima, Picard, Nicolas, Sauvage, Francois-Ludovic, Billat, Pierre-Andre, Analytical and Bioanalytical Chemistry, 2015, 10.1007/s00216-015-8554-0
  • Development and Validation of Multiple Linear Regression Formulas and a Bayesian Estimator for Mycophenolic Acid Long Term Therapeutic Drug Monitoring, Wallemacq, P., Verbeeck, R. K., Marquet, P., Cumps, J., Senessael, J. J., Bosmans, J. L., Rousseau, A., Musuamba, F., Therapeutic Drug Monitoring, 2009
  • Uterus transplantation. Current situation, Aubard, Y., Essig, M., Laskar, M., Gardet, E., Drouet, M., Guillaudeau, A., Pichon, N., Marquet, P., Mesnard, C., Piver, P., Gauthier, T., Gynecologie Obstetrique & Fertilite, 2012, 10.1016/j.gyobfe.2012.09.011
  • Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles, Pierre Marquet, Jean Debord, Jean‐Baptiste Woillard, Marc Labriffe, CPT: Pharmacometrics & Systems Pharmacology, 2022, 10.1002/psp4.12810
  • Towards therapeutic drug monitoring of mycophenolic acid in mucous membrane pemphigoid: A retrospective single-centre study., , Fundamental & clinical pharmacology, 2021, 10.1111/fcp.12688
  • Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations - twice daily Prograf (R) and once daily Advagraf (R), Rousseau, Annick, Rostaing, Lionel, Marquet, Pierre, Kamar, Nassim, de Winter, Brenda C. M., Woillard, Jean-Baptiste, British Journal of Clinical Pharmacology, 2011, 10.1111/j.1365-2125.2010.03837.x
  • Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants, Marquet, P, Paintaud, G, Lachatre, G, Buchler, M, Rousseau, A, Le Meur, Y, Debord, J, Leger, F, Clinical Pharmacokinetics, 2002, 10.2165/00003088-200241010-00006
  • Calcineurin regulation of cytoskeleton organization: a new paradigm to analyse the effects of calcineurin inhibitors on the kidney, Essig, Marie, Marquet, Pierre, Mestre, Elodie, Descazeaud, Virginie, Journal of Cellular and Molecular Medicine, 2012, 10.1111/j.1582-4934.2011.01398.x
  • Low alfentanil target-concentrations improve hemodynamic and intubating conditions during induction with sevoflurane, Feiss, P, Preux, PM, Marquet, P, Benrhaiem, M, Vandroux, D, Nathan, N, Canadian Journal of Anaesthesia-Journal Canadien D Anesthesie, 2004
  • Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers, Dostert, P, Homery, MC, Wodey, E, Marquet, P, Montestruc, F, Pecking, M, British Journal of Clinical Pharmacology, 2002, 10.1046/j.1365-2125.2002.01665.x
  • Can the Area Under the Curve/Trough Level Ratio Be Used to Optimize Tacrolimus Individual Dose Adjustment?, Marquet P, Labriffe M, Saint-Marcoux F, Monchaud C, Woillard JB, Transplantation, 2022, 10.1097/tp.0000000000004405
  • Population Pharmacokinetics and Bayesian Estimators for Refined Dose Adjustment of a New Tacrolimus Formulation in Kidney and Liver Transplant Patients, Marquet, P., Saint-Marcoux, F., Monchaud, C., Debord, J., Woillard, J. B., Clinical Pharmacokinetics, 2017, 10.1007/s40262-017-0533-5
  • Active or passive maternal smoking increases the risk of low birth weight or preterm delivery: Benefits of cessation and tobacco control policies, Yves Aubard, Daniel Thomas, Tristan Gauthier, Pierre Marquet, Conchita Delcroix-Gomez, Michel-Henri Delcroix, Tobacco Induced Diseases, 2023, 10.18332/tid/156854
  • Pharmacology of opiates during pregnancy and in neonates, Kintz, P, Marquet, P, Buprenorphine Therapy of Opiate Addiction, 2002
  • Pharmacological exposure to ribavirin: A key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment, OPTIRIB Grp, Marquet, Pierre, Sautereau, Denis, Pinta, Alexandrina, Zarski, Jean-Pierre, Di Martino, Vincent, Pol, Stanislas, Bourliere, Marc, De Ledinghen, Victor, Trepo, Christian, Alain, Sophie, Babany, Gerard, Maynard, Marianne, Rousseau, Annick, Carrier, Paul, Loustaud-Ratti, Veronique, Digestive and Liver Disease, 2011, 10.1016/j.dld.2011.04.002
  • Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: is there an association with haematological toxicity?, Saint-Marcoux, Franck, Marquet, Pierre, Neely, Michael, Alain, Sophie, Picard, Nicolas, Sauvage, Francois-Ludovic, Essig, Marie, Woillard, Jean-Baptiste, Billat, Pierre-Andre, Journal of Antimicrobial Chemotherapy, 2016, 10.1093/jac/dkv342
  • Cyclosporine A inhibits MRTF-SRF signaling through Na+/K+ ATPase inhibition and actin remodeling., , FASEB bioAdvances, 2019, 10.1096/fba.2019-00027
  • New Tools for Tacrolimus (Tac) Dose Optimization In Lung Transplant Recipients during the First Post-Transplant Year: Preliminary Results of STIMMUGREP Study, Marquet, P., Rousseau, A., Guilllemain, R., Dromer, C., Kessler, R., Pison, C., Reynaud-Gaubert, M., Estenne, M., Monchaud, C., Journal of Heart and Lung Transplantation, 2009
  • Feasibility and Performance of Therapeutic Drug Monitoring of Mycophenolate Mofetil Monotherapy in Liver Transplant, Marquet, Pierre, Duvoux, Christophe, Lamarque, Catherine, Transplantation, 2016
  • Influence of ABCB1 donor genotype on graft loss in a retrospective cohort of renal transplant patients receiving CyclosporineA, Marquet, Pierre, Drouet, Mireille, Rousseau, Annick, Rerolle, Jean-Philippe, Picard, Nicolas, Woillard, Jean-Baptiste, Le Meur, Yannick, American Journal of Transplantation, 2008
  • A general unknown screening procedure for drugs and toxic compounds in serum using liquid chromatography-electrospray-single quadrupole mass spectrometry, Lachatre, G, Dupuy, JL, Duchoslav, E, Marquet, P, Venisse, N, Journal of Analytical Toxicology, 2003
  • Development of a non-parametric population model and a bayesian estimator for tacrolimus in renal Tunisian transplant patients, Woillard, J. B., Marquet, P., Debord, J., Trabelsi, S., Gaies, E., Ben Sassi, M., Fundamental & Clinical Pharmacology, 2017
  • Impact of Two Years of 50% Reduction of Cyclosporine Exposure in Stable Kidney Transplant Recipients Treated with Mycophenolate Mofetil without Corticosteroids on Renal Function- "Results at 60 Months of Follow-Up of a Multicenter Randomized Controlled Trial: The DICAM Study"., Godin, M., Benichou, J., Houivet, E., Francois, A., Marquet, P., Westeel, P. -F., Rerolle, J. -P., de Ligny, B. Hurault, Al Najjar, A., Thierry, A., Toupance, O., Etienne, I., American Journal of Transplantation, 2011
  • Comparison of Tacrolimus Starting Doses Based on CYP3A5 Phenotype or Genotype in Kidney Transplant Recipients., , Progress in transplantation (Aliso Viejo, Calif.), 2019, 10.1177/1526924819873905
  • MRP4 is responsible for the efflux transport of mycophenolic acid β-d glucuronide (MPAG) from hepatocytes to blood., , Xenobiotica; the fate of foreign compounds in biological systems, 2020, 10.1080/00498254.2020.1813352
  • Therapeutic drug monitoring of antidepressants in human serum using a fully automated turbulent-flow - Liquid hromatography - Tandem mass spectrometry technique, Marquet, P, Lachatre, G, Gaulier, JM, Sauvage, FL, Therapeutic Drug Monitoring, 2005
  • Mycophenolic Acid Glucuronides Pharmacologically Active on Inosine MonoPhophate DeHydrogenase Type II (IMPDH II)?, Marquet, P., Picard, N., Gensburger, O., Therapeutic Drug Monitoring, 2009
  • A Time-Dependent Model Describes Methotrexate Elimination and Supports Dynamic Modification of MRP2/ABCC2 Activity, Guellec, C. B. L., Marquet, P., Choquet, S., Abraham, J., Girault, S., Turlure, P., Saint-Marcoux, F., Benz-de-Bretagne, I., Debord, J., Woillard, J. B., Therapeutic Drug Monitoring, 2017, 10.1097/ftd.0000000000000381
  • LOOKING FOR CYCLOSPORINE AUC TARGETS IN RENAL TRANSPLANTATION, Marquet, P., Essig, M., Rerolle, J. P., Woillard, J. B., Saint-Marcoux, F., Beaurain, M., Transplant International, 2013
  • Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome, Harambat, Jerome, Decramer, Stephane, Marquet, Pierre, Bouchet, Stephane, Gandia, Peggy, Brochard, Karine, Morin, Denis, Godron, Astrid, Bandin, Flavio, Ichay, Lydia, Llanas, Brigitte, Saint-Marcoux, Frank, Guigonis, Vincent, Dallocchio, Aymeric, Tellier, Stephanie, Clinical Journal of the American Society of Nephrology, 2016, 10.2215/CJN.00320116
  • LC-MS vs. GC-MS, online extraction systems, advantages of technology for drug screening assays., Marquet, Pierre, Methods in molecular biology (Clifton, N.J.), 2012, 10.1007/978-1-61779-934-1_2

Contribution à l'enseignement aux cycles supérieurs

Étudiant(e)s dirigé(e)s*

Depuis 2009
  • Alana Arrouet - Doctorat - En cours
  • Jodie Llinares - Post-doctorat - En cours
  • Johan Chaniot - Post-doctorat - En cours
  • Gabrielle Jess - Maîtrise avec mémoire - En cours
  • Niraj Patel - Doctorat - En cours
  • Jean-Honoré Julio Henri Laurent - Doctorat - En cours
  • Sara Mattar - Doctorat - En cours
  • Mohamed Haouat - Post-doctorat - En cours
  • Paul Amaury Parant - Doctorat - En cours
  • Corentin Emilien Soubeiran - Doctorat - En cours
  • Céline Larivière-Loiselle - Doctorat - En cours
  • Andréanne Deschênes - Maîtrise avec mémoire - 2019/09
  • Pauline Lavergne - Maîtrise avec mémoire - 2019/09
  • Philippe Bilodeau - Maîtrise avec mémoire - 2019/09
  • Antoine Grégoire - Maîtrise avec mémoire - 2019/09
  • Bertrand De Dorlodot - Maîtrise avec mémoire - 2020/05
  • Christophe Perron - Maîtrise avec mémoire - 2021/01
  • Emile Rioux-Pellerin - Maîtrise avec mémoire - 2021/05
  • Vahid Khojasteh Lazarjan - Doctorat - 2022/09
  • Louis Philippe De Tillieux - Doctorat - 2023/05
  • Louis-Philippe Guinard - Maîtrise avec mémoire - 2023/09

Encadrement d'étudiant(e)s pour les programmes suivants :

Disponibilité d'encadrement d'étudiant(e)s

Ce (cette) professeur(e) est présentement à la recherche d'étudiant(e)s.

Envoyer un courriel
*Les supervisions d’étudiant(e)s de 1er cycle en stage de recherche et de résident(e)s aux études médicales postdoctorales seront répertoriées ultérieurement.